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Abstract 
Colon cancer care provides an important opportunity to identify how providers and policymakers 
can achieve high quality outcomes in the context of quality guidelines. Among patients surgically 
treated for colon cancer, better survival has been demonstrated in those with more lymph nodes 
evaluated. Evaluated at the time of surgery, lymph node involvement (i.e. node positive disease) 
indicates advanced disease among colon cancer patients and a recommendation for adjuvant 
chemotherapy. Over the past 20 years, several practice organizations and consensus panels have 
identified the surgical evaluation of 12 or more lymph nodes as an important quality indicator for 
appropriate staging and treatment of newly diagnosed colon cancer patients. However, the exact 
mechanism behind more extensive lymph node evaluation and improved survival remains 
contentious. Using the Surveillance, Epidemiology and End Results (SEER) data and the SEER-
Medicare data, which combines a set of cancer registry data linked to Medicare administrative 
claims, this research evaluates current gaps in knowledge surrounding the achievement and 
impact of lymph node quality guidelines for colon cancer care by l) further evaluating the 
mechanism between lymph node evaluation and survival 2) identifying whether high quality 
comprehensive care might account for this relationship and 3) understanding how to significantly 
improve guideline adherence among providers of colon cancer care. Overall, this research 
provides timely evidence for future guideline recommendations surrounding the relative impact 
of lymph node evaluation for colon cancer care. 
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Chapter 1: Specific Aims  
 
With over 100,000 new colon cancer cases diagnosed in the United States each year,1 
identifying pathways for improved survival and treatment is critical for reducing the burden of the 
disease on the population.2  Among patients undergoing surgery for colon cancer, better survival 
has been demonstrated in those who have more lymph nodes evaluated.3-7  Lymph node 
involvement indicates more advanced disease and a recommendation for adjuvant chemotherapy 
after surgery.8-10 As a result, several practice organizations and consensus panels have 
recommended the surgical evaluation of 12 or more lymph nodes to facilitate adequate staging 
and appropriate treatment for colon cancer over the past 20 years.11-14  Initially, the primary 
mechanism for this association was believed to be upstaging, where a more extensive evaluation 
of lymph nodes resulted in more accurate determination of nodal status. However, studies have 
demonstrated that higher lymph node counts did not necessarily result in a shift towards higher 
staged colon cancers.15-17 Rather, higher lymph node counts led to improved survival regardless 
of whether they were node positive or negative.18-19  Recently, several groups have advocated two 
alternative hypotheses. First, this relationship may result from an improvement in surgical quality 
and treatment. More experienced, higher volume surgeons and facilities may perform quality 
procedures, evaluating an increased number of nodes in the process.15, 20-21  These patients may 
additionally receive more appropriate adjuvant therapy for their disease, as well as better follow-
up care. Alternatively, the lymph node-survival relationship may reflect an underlying interaction 
between the tumor and individual, influencing survival.22  In other words, tumor factors may 
stimulate lymph nodes to enlarge, reflecting immune system recognition of the tumor and more 
favorable survival outcomes. To date, the literature lacks a consensus on the driving force behind 
the lymph node-survival relationship.  
In order to further understand the relationship between quality, biology and colon cancer 
outcomes, I will use Surveillance, Epidemiology and End Results (SEER) data and the SEER-
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Medicare linked data to identify how this relationship has evolved with the institution of quality 
guidelines over the past 20 years. If quality is the predominate force in this relationship, we 
should see a relationship between guideline recommended lymph node evaluation and other 
markers of high quality care that drive survival. Therefore, the specific aims of my proposed 
research are to: 
 
Specific Aims 
1. Examine the association between more extensive lymph node evaluation, identification of 
lymph node positive cancers and hazard of death over the past 20 years. 
 
2. Examine whether people receiving adequate lymph node evaluation (≥12 nodes examined) are 
also more likely to receive more comprehensive post-surgical care, leading to lower mortality. 
 
3. Determine hospital characteristics associated with improvement or maintenance of guideline-
recommended lymph node evaluation after the first published guidelines in 1990.    
 
Understanding the mechanism that influences the node-survival relationship and leads to 
improved adherence to guideline recommended care will be instrumental in the design of future 
quality improvement programs. While lymph node evaluation alone may not drive improved 
survival, understanding the best combined mechanisms for influencing guideline recommended 
care will be important for identifying those components that significantly improve the quality of 
colon cancer care in the US.  
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Chapter 2: Statement of Purpose and Background 
 
Over the past decades, the development of quality guidelines for best-practice medical 
care has become a priority for policy makers, payers and health care providers.23-24 However, the 
Institute of Medicine continues to identify significant gaps between knowledge and practice for 
health care delivery.23 With the growing complexity of care combined with an aging population, 
the US healthcare system will require specific mechanisms for identifying how high quality care 
can be achieved. In the context of wide-ranging quality improvement efforts in medical care,25 
optimizing cancer care through accurate staging and appropriate treatment has become an area of 
substantial interest to policy makers as it identifies appropriate therapeutic decision-making and 
prognostic estimates.23-25   
 Colon cancer care provides an important opportunity to identify how providers and 
policymakers can achieve high quality outcomes in the context of quality guidelines. Over the 
past 20 years, several practice groups and consensus panels including one convened by the 
National Cancer Institute identified the surgical evaluation of 12 or more lymph nodes as an 
important quality indicator for appropriate staging of newly diagnosed colon cancer patients.13-14, 
26 Among patients surgically treated for colon cancer, better survival has been demonstrated in 
those with more lymph nodes evaluated.6  Lymph node involvement indicates advanced disease 
among colon cancer patients and a recommendation for adjuvant chemotherapy.8-10  
In the context of rising healthcare costs, identifying and treating those patients most 
likely to benefit from adjuvant therapy remains an import goal; particularly when over 104.1 
billion dollars are spent each year in the US on cancer care alone.27  In the near future, cancer care 
costs may actually increase at a faster rate than general medical expenditures. Therefore, 
understanding where to focus quality guidelines remains important for influencing both cancer 
outcomes and rising healthcare costs. However, significant criticisms have emerged regarding the 
suitability of the lymph node evaluation guideline to significantly improve survival and outcomes 
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in colon cancer patients. Initially, the primary mechanism for this association was believed to be 
upstaging. In other words, a more extensive evaluation of lymph nodes resulted in more accurate 
determination of nodal status. However, studies from large multicenter institutions and population 
based analyses have demonstrated that higher lymph node counts did not result in a shift towards 
higher staged colon cancers.16-17 Rather, higher lymph node counts resulted in improved survival 
regardless of whether they were node positive or negative.17-18  
Recently, several groups have criticized the proposed mechanism between nodal 
evaluation and survival, advocating two alternative hypotheses.16, 22  First, this relationship may 
result from an improvement in surgical quality and treatment. More experienced, higher volume 
surgeons and facilities may perform higher quality procedures, evaluating an increased number of 
nodes in the process. Additionally, these patients may receive more appropriate adjuvant therapy 
for their disease and more comprehensive follow-up care. Second, this relationship between 
nodes evaluated and survival may reflect an underlying interaction between the tumor and 
individual, influencing survival.22  In other words, tumor factors may stimulate lymph nodes to 
enlarge, reflecting immune system recognition of the tumor and more favorable survival 
outcomes. 
In order to further understand the relationship between quality, biology and cancer 
outcomes, several studies have examined predictors of adequate lymph node evaluation and their 
impact on survival. In these studies, patient, surgeon and hospital characteristics all emerge as 
significant predictors of both nodal evaluation and cancer-specific survival, indicating that both 
biology and quality may drive survival outcomes.21, 28  Further, a study by Nathan et al.21 
identified that high performing hospitals (i.e. those evaluating ≥12 nodes on average) were more 
likely to have board certified colon surgeons conducting the operation and participate in 
cooperative cancer groups, both indicators of specialized experience and dedicated cancer 
resources. Further, they found that after accounting for patient demographics and tumor 
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characteristics, the majority of modifiable variation in guideline-recommended evaluation occurs 
at the hospital level.21 These results point towards institutional quality as an important driver of 
guideline adherence and outcomes. However, in 2002, over 60% of hospitals were still 
performing below guideline recommendations for lymph node evaluation, five years after they 
were published.28  
If quality is indeed the driving mechanism between lymph node evaluation and survival, 
hospitals and providers then need concrete recommendations for how they can continue to 
improve quality and influence their colon cancer outcomes. First, further understanding the 
mechanism that influences the node-survival relationship will be instrumental in the design of 
future quality improvement programs. Growing evidence suggests that lymph node evaluation 
alone does not drive improved survival.16, 22 Rather, it may be the combination of good quality 
surgical care with better access to adjuvant therapy. Second, identifying specific changes in 
hospital organization, specialty membership or physician composition will be important to 
identify those components that significantly influence quality of colon cancer care in the US. 
Currently, literature on lymph node evaluation focuses predominately on predictors of adequate 
lymph node evaluation- not on predictors of improvement in lymph node evaluation. Such an 
analysis will provide specific recommendations for improving quality measures for colon cancer 
care. 
Overall, the proposed research will evaluate current gaps in knowledge surrounding the 
achievement and impact of lymph node quality guidelines for colon cancer care by 1) further 
evaluating the mechanism between lymph node evaluation and survival 2) identifying whether 
high quality comprehensive care might account for this relationship and 3) understanding how to 
significantly improve guideline adherence among providers of colon cancer care. The current lack 
of consensus on where to focus quality improvement efforts in the context of colon cancer 
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suggests that the proposed research will provide timely and significant evidence for future 
guideline recommendations.     
Relationship between Lymph Node Evaluation for Colon Cancer and Survival 
 
Current literature on the relationship between lymph node evaluation and survival 
indicates that the number of lymph nodes evaluated after surgical resection is positively 
associated with survival in patients with stage II (lymph node negative) and stage III (lymph node 
positive) colon cancers. A systematic review by Chang et al. identified seventeen retrospective 
studies evaluating the relationship between lymph node evaluation and survival (Table 1).6 
Although methodologies were variable, all but one study found an association between having an 
increased number of lymph nodes evaluated and improved survival in patient with both node 
positive and node negative disease.  
Table 1: Studies evaluating the association between lymph node evaluation and survival 
Population Stage Study Design Comparison Outcomes Timing Study 
3,322 colon 
cancer 
patients who 
underwent 
complete 
resection of 
the primary 
tumor  
II 
and 
III 
Retrospective 
Nested 
Cohort 
10-year OS, 
CSS 
Stage II 
75% overall 
survival with 
11-20 nodes 
examined, 
59% <11 
nodes, 
p<0.001 
 
Stage IIIB 
 
>64% 
overall 
survival with 
11-40 nodes 
examined, 
56% <11 
nodes, 
p<0.001 
 
 
 
 
 
1988-
97 
Le Voyer 3 
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Table 1 (Continued) 
Population Stage Study Design Comparison Outcomes Timing Study 
3,648 colon 
cancer 
patients who 
underwent 
complete 
resection of 
the primary 
tumor 
II 
and 
III 
Retrospective 
Nested 
Cohort 
5-year OS; 
DFS 
>76% 
overall 
survival with 
≥12 nodes 
examined, 
69% <11 
nodes, 
p<0.0097 in 
stage II and 
III 
 
1995 
with a 
median 
follow-
up of 
3.6 
years 
Prandi29  
35,787 
prospectively 
collected 
cases of 
T3N0MO 
colon cancer, 
surgically 
treated  
II Prospective 
cohort study 
5-year OS 64% if 1-2 
lymph nodes 
evaluated to 
86% if >25 
nodes 
evaluated, 
p<0.001 
1985-
1991 
Swanson7 
960 
randomly 
selected 
colon cancer 
patients who 
underwent 
major colon 
resection in 
the Ontario 
Cancer 
Registry 
I, II, 
and 
III 
Retrospective 
cohort study 
OS HR 0.6 (0.4, 
1.0) in node 
negative 
patients with 
10-36 nodes 
evaluated vs. 
1-3, p=0.03 
1991-
1993 
Bui4 
2437 colon 
cancer 
patients from 
the Kentucky 
Cancer 
Registry 
II 
and 
III 
Retrospective 
cohort study 
OS 56% if <12 
lymph nodes 
evaluated vs. 
63% if >12 
evaluated, 
p<0.001 
N/A Carloss30 
8574 colon 
cancer 
patients from 
SEER cancer 
registries 
II Retrospective 
cohort study 
5 and 10 
year OS 
HR: 0.98 
(0.97, 0.98) 
for each 
additional 
lymph node 
evaluated, 
p<0.01 
1988-
1998 
Cserni31 
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Table 1 (Continued) 
Population Stage Study Design Comparison Outcomes Timing Study 
3735 colon 
cancer 
patients  
from the 
Uppsala 
cancer 
registry 
II 
and 
III 
Retrospective 
cohort study 
5 year OS 65% if <11 
lymph nodes 
evaluated vs. 
75% if ≥11 
evaluated, 
p<0.001 
1997-
2002 
Jestin32 
745 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II Retrospective 
cohort study 
5 year OS 62% if <7 
lymph nodes 
evaluated vs. 
76% if ≥18 
evaluated, 
p<0.018 
1955-
2000 
Goldstein33 
480 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II Retrospective 
cohort study 
5 year OS 51% if <10 
lymph nodes 
evaluated vs. 
71% if ≥19 
evaluated, 
p<0.045 
1980-
2000 
Sarli34 
222 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II Retrospective 
cohort study 
5 year OS 49% if <7 
lymph nodes 
evaluated vs. 
68% if 
≥7evaluated, 
p<0.001 
1985-
1990 
Caplin35 
140 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II Retrospective 
cohort study 
5 year OS 62% if <7 
lymph nodes 
evaluated vs. 
86% if 
≥7evaluated, 
p<0.03 
1988-
1995 
Cianchi36 
179 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II 
and 
III 
Retrospective 
cohort study 
5 year OS Stage II 
72% if <9 
lymph nodes 
evaluated vs. 
85% if 
≥9evaluated, 
p<0.35 
 
Stage III 
55% if <9 
lymph nodes 
evaluated vs. 
78% if ≥9 
evaluated, 
p<0.01 
1997-
2003 
Gumus37 
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Table 1 (Continued)  
Population Stage Study Design Comparison Outcomes Timing Study 
115 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II  Retrospective 
cohort study 
5 year OS 62% if <7 
lymph nodes 
evaluated vs. 
86% if ≥7 
evaluated, 
p<0.03 
 
1994-
1999 
Law38 
487 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
I, II, 
III 
Retrospective 
cohort study 
5 year OS Stage I- II 
83% if <11 
lymph nodes 
evaluated vs. 
91% if ≥29 
evaluated, 
p<0.35 
 
Stage III 
59% if <11 
lymph nodes 
evaluated vs. 
84% if ≥29 
evaluated, 
p<0.01 
1981-
1996 
Ratto39 
487 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II Retrospective 
cohort study 
5 year OS Statistically 
significant 
improvement 
in survival 
with ≥14 
lymph nodes 
evaluated 
versus <14, 
exact 
survival 
rates not 
reported 
1995-
1999 
Wong40 
94 colon 
cancer 
patients 
diagnosed in 
a single 
institution 
II Retrospective 
cohort study 
5 year OS 49% if <7 
lymph nodes 
evaluated vs. 
68% if ≥7 
evaluated, 
p<0.001 
 Yoshimatsu41 
* OS: Overall Survival; CSS: Cancer Specific Survival; DFS: Disease Free Survival; HR: Hazard 
Ratio 
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Potential Confounders of the Lymph Node Evaluation-Survival Relationship 
Patient Factors 
Each of the observational studies (Table 1) examining the relationship between lymph 
nodes and survival adjusts for differing combinations of patient, surgeon and hospital factors that 
might influence the relationship between lymph node evaluation and outcomes. For patient 
factors, these studies most often adjusted for patient age, gender, race, extent of disease, and 
adjuvant therapy (Table 2).  However, these previous studies evaluated the relationship between 
lymph node evaluation and survival in select groups, which are based on single-institution 
findings, limited to the elderly or evaluated in patients diagnosed with specific AJCC stages. As a 
result, these studies may not fully capture the true relationship between nodal evaluation and 
survival when the association is evaluated in a large population-based sample of all surgically-
treated colon cancer patients.  
Table 2: Patient confounders included in studies evaluating the relationship between lymph 
node evaluation and survival 
Study Age Gende
r 
Co- 
morbidity 
Histology
/ Grade 
Extent 
of 
disease 
Socio-
economic 
status 
Insuranc
e 
Adjuvant 
Therapy 
Le Voyer3 X X  X X   X 
Prandi29 X X  X X    
Swanson7 X   X    X 
Bui4 X X X X X    
Carloss30 N/A        
Cserni31 X X  X X   X 
Jestin32 X X  X     
Goldstein33    X     
Sarli34 X X  X X   X 
Caplin35 X X       
Cianchi36 X X  X X    
Gumus37 N/A        
Law38 X  X      
Ratto39 X   X X    
Wong40 N/A        
Yoshimatsu
41 
N/A        
N/A: Unadjusted analyses only 
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Surgeon and Hospital Factors 
Few studies adjust for hospital factors when assessing the association between lymph 
node evaluation and overall survival. Specifically, only one of the above studies explicitly 
mentions the potential confounding effect of these factors on survival. Bui et al. examine factors 
including teaching status, hospital volume, emergent surgeries.4 However, several studies have 
demonstrated an association between additional hospital characteristics and survival including 
cooperative cancer group membership and hospital network characteristics. Further, no study 
accounted for variation in surgeon characteristics as a potential mediator between lymph node 
evaluation and survival. 
Receipt of Recommended Post-surgical care 
 While the underlying mechanism for the relationship between lymph node evaluation and 
improved survival remains controversial, several groups have proposed that adequate lymph node 
evaluation may actually be an underlying marker of more comprehensive, higher-quality care.16, 
18, 22  Specifically, patients with more extensive lymph node evaluation may be more likely to 
receive guideline-recommended adjuvant therapy for their disease as well as more extensive 
follow-up and surveillance care. Current practice guidelines recommend that patients with AJCC 
stage III42 (i.e. lymph-node positive disease) receive adjuvant chemotherapy and a series of post-
surgical surveillance exams in the period following treatment in order to monitor disease 
progression and control. 13, 43-46 While previous research has identified an independent association 
between adequate lymph node evaluation,13 adjuvant therapy,42 comprehensive post-surgical 
care13, 43-46 and lower mortality, no study has systematically evaluated how these combined 
interventions influence mortality. 
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Factors Associated with Adequate Lymph Node Evaluation during Colon Cancer Resection 
Patient Factors 
Current studies evaluating factors associated with adequate lymph node evaluation have 
specifically examined patient, surgeon and hospital factors that influence evaluation. However, 
they examine adequate evaluation as a benchmark and not a relative increase in performance. 
Specifically, patient factors including age, race, gender, insurance and extent of disease have all 
been demonstrated to influence removal of a higher number of lymph nodes (Table 3). Again, 
these studies do not account for additional unobserved confounders and fail to acknowledge that 
selection bias may be driving this relationship, particularly when certain individuals are likely to 
go to better quality surgeons or institutions. 
Table 3: Patient Factors Associated with Adequate Lymph Node Evaluation for Colon 
Cancer 
 
Study Age Gender Race Histology
/ Grade 
Extent 
of 
diseas
e 
Co-
morbidit
y 
Insurance 
Baxter19 X X  X X  X 
Bilimoria28 X X X X X   
Nathan21 X X X X X X X 
 
 
 
Surgeon Factors 
 Surgeon factors that influence a higher lymph node evaluation are fairly limited in the 
literature. Specifically, only two studies have evaluated the impact of surgeon specialty and 
volume on the likelihood of adequate lymph node evaluation for colon cancer.21, 28 Literature 
from the general surgical field indicates that several other factors may influence outcomes or 
quality measures including physician experience, board certification and years since medical 
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school. Specifically, physician age up to 50 years and more than 10 years of experience are 
associated with higher adoption rates of new procedures and techniques.47  Further, physicians in 
solo practice in non-urban locations adopted the least number of new procedures annually, which 
was thought to be related to a lower amount of peer exposure to the use of new procedures or 
guidelines. 
 
Hospital Factors 
 
Several hospital characteristics have been significantly associated with adherence to 
guideline recommended lymph node evaluation. In a study of the National Quality Database, 
hospital type including NCI designated comprehensive cancer centers and academic institutions 
were significantly more likely to follow recommended evaluation guidelines.28 Additionally, a 
study of elderly colon cancer patients identified the same hospital characteristics as predictive of 
higher lymph node evaluation.21 However, no study has specifically evaluated how nodal 
evaluation prior to the implementation of guidelines was associated with performance after 
guidelines were published.  
Limitations to Current Research 
 Current literature evaluating both predictors of lymph node evaluation and its ability to 
significantly influence survival are limited both in the extent to which potential confounders are 
addressed and their discussions regarding how improvement in quality guideline adherence might 
be achieved. This gap in knowledge presents an opportunity to further evaluate predictors of 
improvement in lymph node evaluation- not just the attainment of the quality measure. Further, 
current research is limited in the extent to which hospital factors drive the node evaluation-
survival relationship. Studies fully incorporating these confounding factors may demonstrate that 
the survival relationship is more likely attributable primarily to hospital quality.  
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Conceptual Model 
 As seen in the literature review, three main groups of factors influence the adequacy of 
lymph node evaluation for colon cancer patients: patient, surgeon and hospital characteristics 
(Figure 1). Although the surgeon is ultimately responsible for the surgical treatment and extent of 
lymph node dissection, multiple patient characteristics can influence the treating surgeon. In 
addition to specific tumor characteristics, patient factors such as age, extent of comorbidities and 
the number of nodes present can all impact the number of nodes evaluated as well as survival.  
 
Figure 1: Conceptual Model of Factors that Influence Receipt of Adequate Lymph Node 
Evaluation and Receipt of Recommended Post-Surgical Care  
   
Conceptual Model
Demographics
Age, Race
Lymph Node 
Evaluation Treatment Survival
Biology/
Tumor Factors
Provider/Hospital 
Attributes
Year of 
Diagnosis
Paper 1Paper 3
Paper 2
Node Positivity
Lymph Node Evaluation and Survival: Is it biology or is it quality?
 
 
In addition to patient factors, surgeon factors significantly influence technique, 
knowledge and experience, which all differentially influence the likelihood of adequate lymph 
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node evaluation. Specifically, a surgeon’s specialty, professional certification, years in practice 
and surgical volume all influence the ability to identify lymph nodes during surgical resection. 
Although a surgeon’s decision to identify a larger number of lymph nodes should be independent 
of patient characteristics, tumor characteristics or unmeasured biological changes may influence a 
provider’s ability to identify lymph nodes. 
Lymph node evaluation can also be significantly influenced by hospital characteristics, 
which can influence the culture or expectations of surgical resection for individual surgeons. 
These factors include those characteristics that are known to influence other cancer quality 
outcomes such as survival. Such characteristics include hospital volume for colon procedures, 
type of ownership, teaching status and membership in a cancer cooperative group.  
Receipt of adjuvant therapy, while also influenced by patient, provider and hospital 
characteristics, is modified by the receipt of adequate lymph node evaluation. In other words, 
individuals undergo adequate lymph node evaluation are more likely to receive quality care along 
the cancer continuum. Once they enter a high quality system, they continue to receive appropriate 
therapy in a timely manner.  
Contribution of the Dissertation to Previous Work 
Understanding the mechanism that influences the node-survival relationship and leads to 
improved adherence to guideline recommended care will be instrumental in the design of future 
quality improvement programs. While lymph node evaluation alone may not drive improved 
survival, understanding the best combined mechanisms for influencing guideline recommended 
care will be important for identifying those components that significantly improve the quality of 
colon cancer care in the US.  
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Chapter 3: Association between Lymph Node Evaluation for Colon Cancer and Node 
Positivity over the Past 20 Years48 
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Context: Among patients surgically treated for colon cancer, better survival has been 
demonstrated in those with more lymph nodes evaluated. The presumed mechanism behind this 
association suggests that a more extensive lymph node evaluation reduces the risk of 
understaging, leading to improved survival. 
 
Objective: To further evaluate the mechanism behind lymph node evaluation and survival, we 
examined the association between more extensive lymph node evaluation, identification of lymph 
node positive cancers and hazard of death. 
 
Design: Observational cohort study 
 
Setting: 1988-2008 Surveillance, Epidemiology and End Results (SEER) Program 
 
Patients: 86,394 surgically treated colon cancer patients 
 
Main outcome measure: We examined the relationship between lymph node evaluation and 
node positivity using Cochran-Armitage tests and multivariate logistic regression. The association 
between lymph node evaluation and hazard of death was evaluated using Cox Proportional 
Hazards modeling. 
 
Results: The number of lymph nodes evaluated increased from 1988 to 2008, but did not result in 
a significant overall increase in lymph node positivity. During 1988-1990, 34.6% 
(n=3,875/11,200) of patients had ≥12 lymph nodes evaluated, increasing to 73.6% 
(n=9,798/13,310) during 2006-2008 (p<0.001); however, the proportion of node positive cancers 
 18 
did not change with time (40% in 1988-1990 vs. 42% in 2006-2008 (p=0.53)). Although patients 
with high levels of lymph node evaluation were only slightly more likely to be node positive 
(adjusted odds ratio for 30-39 nodes vs. 1-8 nodes, 1.11; 95% Confidence Interval (CI), 1.02-
1.20), these patients experienced significantly lower hazard of death compared with those with 
fewer nodes evaluated (adjusted hazard ratio for 30-39 nodes vs. 1-8 nodes, 0.66; 95% CI, 0.62-
0.71).  
  
Conclusions: The number of lymph nodes evaluated for colon cancer has markedly increased in 
the past two decades but was not associated with an overall shift toward higher staged cancers, 
questioning the upstaging mechanism as the primary basis for improved survival in patients with 
more lymph nodes evaluated. 
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Background 
As wide-ranging quality improvement efforts emerge throughout the healthcare system,23 
finding mechanisms for optimizing cancer care through accurate staging and appropriate 
treatment has become an area of substantial interest to policy makers. Among patients surgically 
treated for colon cancer, several studies have demonstrated better survival for patients with more 
lymph nodes evaluated. Reported survival improvements among those with higher lymph node 
counts have approached 20% in some settings.3, 6 The proposed mechanism behind this 
association suggests that a more extensive lymph node evaluation reduces the risk of 
understaging- in which inadequate assessment may incorrectly identify a patient with node-
positive disease as node negative, thus failing to identify appropriate treatment. Based on these 
studies, most practice organizations and consensus panels now advocate for the surgical 
evaluation of 12 or more lymph nodes for acceptable staging of newly diagnosed colon cancer 
patients,14, 26 although individual studies vary widely in their recommendations for the number of 
evaluated nodes necessary to accurately determine nodal status.6, 22 
Recently, some studies have questioned the understaging mechanism, suggesting that 
efforts by payers and professional associations to increase the number of lymph nodes evaluated 
during colon cancer surgery may have a limited role in improving survival.12, 15-16 On a hospital 
level, increasing the number of lymph nodes evaluated following colectomy for colon cancer has 
not been demonstrated to improve staging or survival in patients 65 year and older.16 Other 
studies have suggested that while patients may experience improved staging when more lymph 
nodes are identified, the relationship between the number of nodes evaluated, staging, and 
survival is not simple, with higher lymph node evaluation not necessarily leading to finding 
higher staged cancers in select populations.17  Combined, these results question the hypothesis 
that minimizing understaging is the underlying mechanism for the relationship between lymph 
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node evaluation and improved survival. We analyzed 20-year trends in the degree of lymph node 
evaluation for colon cancer and how they are associated with survival. 
Methods  
 
Data 
We used the 1988-2008 Surveillance, Epidemiology, and End Results (SEER 9) cancer 
registry data. Sponsored by the National Cancer Institute, SEER collects and publishes cancer 
incidence, treatment and survival data from population-based cancer registries covering 
approximately 28% of the US population.49-50 Specifically, SEER collects information on patient 
age, race/ethnicity, sex, year of diagnosis, tumor registry location, tumor depth, tumor grade, 
number of lymph nodes evaluated, number of positive lymph nodes and first course of treatment 
(not including chemotherapy). Overall and cancer-specific mortality are also reported, but not 
recurrence. A 98% case ascertainment is mandated, with annual quality-assurance studies.49 This 
study was approved by the University of Minnesota Institutional Review Board. 
Patients  
Included in our study were patients >18 years who were diagnosed with their first 
invasive adenocarcinoma of the colon from January 1, 1988, through December 31, 2008.  We 
included only patients who underwent radical resection of their colon cancer as the first course of 
treatment according to SEER and would, therefore, be eligible for nodal evaluation.  
Excluded from our study were patients whose cancer was diagnosed by autopsy or first 
cited on the death certificate; patients who underwent preoperative irradiation (as it may reduce 
the ability of surgeons to perform adequate nodal evaluation);51 and patients with an unknown 
number of nodes examined.  
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Assessment of Lymph Node Evaluation and Node Positivity 
Beginning in 1988, SEER has routinely recorded the number of nodes pathologically examined 
for each patient as well as the presence and number of positive lymph nodes (as a continuous 
measure). We categorized patients according to their level of lymph node evaluation in two ways, 
1) receipt of ≥12 lymph nodes (yes/no), which is generally considered an acceptable level of 
lymph node evaluation for determining nodal status based on several clinical guidelines,13-14, 26 
and 2) a series of smaller lymph node categories (0, 1-8, 9-11, 12-15, 15-19, 20-29, 30-39, and 
≥40)  that allow for more extensive evaluation of the effect of lymph node evaluation on each 
outcome. We additionally categorized patients according to node positivity (yes/no), with at least 
one positive lymph node recorded as an indication of lymph node-positive disease. 
Statistical Analysis and Outcomes  
 We evaluated differences in nodal evaluation, node positivity and patient characteristics 
across years of diagnosis, which were categorized into seven groups: 1988-1990, 1991-1993, 
1994-1996, 1997-1999, 2000-2002, 2003-2005 and 2006-2008. First, we tested for trends in the 
proportion of patients with ≥12 lymph nodes evaluated and those with node-positive disease over 
time using the Cochran-Armitage test. Additionally, we evaluated differences in lymph node 
evaluation (using the smaller categories) and patient characteristics across time using the chi-
square test.   
After assessing this unadjusted relationship, we used logistic regression to examine the 
association between lymph node evaluation, patient demographics, tumor characteristics and 
relative odds of node positivity among those with at least one lymph node evaluated (yes/no).  
Finally, we evaluated the association between lymph node evaluation and 5-year hazard of death 
using Kaplan-Meier methods and Cox Proportional Hazards modeling. Kaplan-Meier methods 
were used to estimate unadjusted 5-year cumulative mortality across patient factors. Then, using 
patients as the unit of analysis, logistic regression and Cox models were adjusted for the level of 
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lymph node evaluation, age group (>50, 50-59, 60-69, 70-79, ≥80 years), race (White, Black, 
Other), sex, tumor extent (AJCC stage or T-stage), grade, tumor location, type of surgical 
resection according to SEER, receipt of post-operative radiation (yes/no), year of diagnosis, and 
registry.  
There are additional factors that may explain survival that we could not include in our 
models. For example, we believe chemotherapy is part of the causal pathway between higher 
rates of lymph node evaluation and improved survival for patients with lymph node positive 
disease. That is, chemotherapy does not cause more lymph nodes to be evaluated, but those with 
higher lymph node evaluation may be more likely to receive chemotherapy when indicated (e.g. 
AJCC stage III disease), leading to improved survival.16 However, SEER does not release receipt 
of adjuvant chemotherapy to researchers. As a result, differences in 5-year hazards of death will 
necessarily reflect the composite effect of lymph node evaluation in addition to other quality 
indicators such as chemotherapy. To take this potential factor into account, we stratified our 
results by nodal status at diagnosis to examine the relationship between nodal evaluation and 
survival among those with either node positive (AJCC stage III and IV) or node negative (AJCC 
stage I and II) disease.  
In all models, we performed several sensitivity analyses (e.g. interaction analyses 
[Appendix 1], stratified analyses [Appendices 2 and 3] alternative category groupings [Appendix 
4], removal of non-significant factors [Appendices 5 and 6]) to ensure that the observed effects 
were not an artifact of our modeling decisions. Because the effect of lymph node evaluation on 
odds of node-positivity may vary by tumor extent (e.g. T-stage) and patient characteristics (e.g. 
age at diagnosis), we tested for interactions between lymph node evaluation and these factors in 
all multivariate models. Further, because AJCC staging classifications are dependent on nodal 
status to determine stage and have changed over time,52  we focused on T-stage as our proxy for 
tumor extent when evaluating factors associated with node positivity; however, both were 
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considered independently in the survival models [Appendix 7].  T-stage is defined as the depth of 
bowel penetration of the tumor in the colon, with more extensive bowel penetration indicative of 
more advanced T-stage.53 Lymph nodes are not taken into account when assigning T-stage. Under 
all assumptions, conclusions remained unchanged. See Appendices 1- 7 for complete description 
of sensitivity analysis results. 
We used SAS version 9.1(SAS Institute Inc., Cary, North Carolina) for all analyses. All 
comparisons were pre-planned. P-values were 2-sided with a level of significance of ≤ 0.05. 
Results 
 
          We identified 86,394 surgically-treated patients diagnosed with a primary invasive colon 
cancer from 1988 through 2008 in the SEER program after excluding patients with cancers 
diagnosed by autopsy or first cited on the death certificate (n=81); those who underwent 
preoperative irradiation (n=216) and those who had an unknown number of nodes evaluated 
(n=3,537). Over time, the distribution of patients shifted to those younger at diagnosis, with a 
higher proportion of proximal and T-stage 1 tumors (Table 4). Specifically, the proportion of 
patients diagnosed at <50 years of age increased from 6% (n=715) to 9% (n=1,234) between 
1988-90 and 2006-08 (p<0.001). Over the same time period, the proportion of proximal tumors in 
the cohort increased from 55% (n=6,191) in 1988-1990 to 61% (n=8,231) in 2006-2008 periods 
(p=0.0001). Additionally, these patients were diagnosed at an earlier AJCC-stage, with only 16% 
(n=1,795) of tumors classified as AJCC stage I in 1988-1990 compared to 24.6% (n=3,270) in 
2006-08 (p<0.001). 
Changes in Lymph Node Evaluation over Time  
           Lymph node evaluation for colon cancer increased markedly from 1988 to 2008 (Table 4). 
During 1988-1990, only 34.6% (n=3,875) of patients were receiving acceptable (≥12) lymph 
node evaluation (Figure 2 and Table 4). By 1994-1996, 37.9% (n=4,362) of patients had ≥12 
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lymph nodes evaluated, with 46.8% (n=6,175) receiving this level of evaluation in 2000-2002 and 
73.6% (n=9,798) in 2006-2008 (p<0.001).   
Proportion of Node Positive Cancers over Time  
      Although the number of lymph nodes evaluated increased significantly over time, this change 
did not result in an increase in node positive cancers over the period 1988 to 2008 (p=0.53) 
(Figure 3). However, between T-stages, there were statistically significant but clinically modest 
increases in the proportion of node positive cancers as rates of lymph node evaluation increased. 
While patients with T-stage 2 tumors had relatively consistent rates of node positivity over time 
(16.8% in 1988-1990 to 19.1% in 2006-2008), those with T-stage 3 tumors had statistically 
significant increases in node positivity (38.8% in 1988-1990 to 49.8% in 2006-2008, p<0.001) in 
addition to T-1 and T-4 tumors (Figure 3).  
Association between Lymph Node Evaluation and Node Positivity 
In our study, 96.9% (n=83,671) of surgically-treated colon cancer patients had at least 
one lymph node evaluated (Table 5). Among these individuals, multivariate analyses 
demonstrated that, after adjusting for patient, tumor, and initial treatment factors, those with 
adequate lymph node evaluation (Model 1) were significantly more likely to have node-positive 
disease (adjusted odds ratio (OR) ≥12 vs. <12 nodes, 1.13; 95% Confidence Interval (CI), 1.09-
1.17). However, those with very high levels of lymph node evaluation (Model 2) were only 
slightly more likely to be node positive compared to those with few nodes evaluated (adjusted OR 
for 30-39 nodes vs. 1-8 nodes, 1.11; 95% CI, 1.02-1.20). In addition to lymph node evaluation, 
younger age, higher T-stage and tumor grade were all associated with higher odds of node 
positivity. Interestingly, patients diagnosed in later years were also more likely to have node-
positive disease (adjusted OR 2006-2008 vs. 1988-1990, 1.23; 95% CI, 1.16-1.30), after adjusting 
for level of lymph node evaluation. 
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Association between Lymph Node Evaluation and Mortality 
            Overall 5-year cumulative mortality was 46.9% (n=36,435) in our study for all surgically 
treated patients diagnosed with AJCC stage I-IV colon cancer. Although patients with higher 
levels of lymph node evaluation were only slightly more likely to have node-positive disease, 
these patients experienced significantly lower relative hazard of 5-year death compared to those 
with fewer nodes evaluated (adjusted hazard ratio (HR) for 30-39 nodes vs. 1-8 nodes, 0.66; 95% 
CI, 0.62-0.71) (Table 6a). When stratified by node positivity, patients with node positive disease 
(AJCC stages III and IV, adjusted HR for 30-39 nodes vs. 1-8 nodes 0.73; 95% CI 0.67-0.79) as 
well as node negative disease (AJCC stages I and II, adjusted HR for 30-39 nodes vs. 1-8 nodes 
0.54; 95% CI 0.48-0.62) continued to experience lower relative hazard of death when more 
lymph nodes were evaluated (Table 6b). In addition to higher lymph node evaluation, distal 
cancer site and a later year of diagnosis were also associated with lower relative hazard of death. 
Older age at diagnosis, black race, more advance AJCC stage, and high tumor grade were all 
associated with higher 5-year relative hazard of death (p<0.05 for all). 
Discussion 
  
              In this population-based study of patients surgically treated for colon cancer from 1988 
through 2008, we found marked increases in lymph node evaluation over the past two decades. 
However, this improvement in lymph node evaluation has not been associated with an increase in 
the overall proportion of cancers that are node positive in the population. While patients with high 
levels of lymph node evaluation were only slightly more likely to be node positive than those 
with few nodes evaluated, patients with both node positive as well as node negative disease had 
significant reductions in mortality hazard attributable to high node counts. The combination of no 
substantive change in the proportion of patients with positive nodes concurrent to a large secular 
increase in the number of lymph nodes examined and the paradoxically better survival in patients 
with node negative compared to node positive disease who have greater numbers of nodes 
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examined suggests that upstaging cannot be the mechanism underlying the relationship between 
increased lymph node evaluation and colon cancer survival. 
Initially, the primary mechanism for the observed association between more extensive 
lymph node evaluation and improved survival was believed to be upstaging. In other words, a 
more extensive evaluation of lymph nodes would result in more accurate identification of lymph 
node positive cancers. However, in a hospital-level analysis of surgically treated colon cancer 
patients aged 65 years and older, Wong et al. found no evidence of better 5-year survival among 
hospitals with higher levels of lymph node evaluation.16 Further, they found that regardless of the 
number of lymph nodes a hospital evaluated, they were equally likely to find node positive 
tumors. In another study of surgically treated colon cancer patients with T3 disease, Baxter et al.17 
found that the odds of finding node positive cancers increased in patients with more lymph nodes 
evaluated- but only to a point. While the proportion of their patients found to with node positive 
disease increased with larger nodal counts at low levels (1-6 nodes), those with 7 nodes evaluated 
were as likely as patients with >30 nodes evaluated to be node positive- suggesting that other 
unmeasured factors may lead to identification of node positive disease, potentially influencing 
survival.   Bui et al. further examined this relationship, noting that among patients with node-
negative disease from the Ontario Cancer registry, higher lymph node counts were associated 
with improved survival; however patients with node-positive disease were not simultaneously 
evaluated.4  
Our study builds on these previous studies conducted in select groups, presenting a 
population-based analysis of the relationship between lymph node evaluation, upstaging, and 
survival that is representative of adult colon cancer patients in the US and not limited to the 
elderly individuals or specific AJCC stages. After adjusting for patient, tumor and primary 
treatment factors, we found patients with node-negative disease had  lower 5-year mortality when 
more lymph nodes were evaluated. This effect was unexpectedly larger than that observed for 
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patients with node positive disease. These findings suggest that providers who evaluate more 
lymph nodes may provide some other unmeasured care, leading to better outcomes. Alternatively, 
the relationship between nodes evaluated and survival may reflect an underlying interaction 
between the tumor and individual, influencing survival.16, 22  In other words, tumor factors may 
stimulate lymph nodes to enlarge, reflecting immune system recognition of the tumor and more 
favorable survival outcomes. Although our results cannot provide insight into which mechanism 
underlies the observed patterns, our findings do indicate that more extensive lymph node 
evaluation unlikely leads to improved survival primarily through the more accurate detection of 
node-positive disease.  These findings suggest that other factors besides upstaging, such as 
improved surgical quality or post-surgical care, may be the driving mechanism behind the lymph 
node-survival relationship. As a result, implementing wide-range quality-improvement initiatives 
to increase lymph node evaluation for colon cancer may have a limited effect on improving 
survival in this population. 
Our results also confirm prior studies that indicate younger age,17  more advanced tumor 
depth54-55 and high tumor grade17 are all important predictors of node-positivity in the population. 
Further, we identify year of diagnosis as an additional predictor of node-positivity, which may 
result from the adoption of new pathology or surgery techniques for harvesting lymph nodes or 
identifying micrometastases.56-58 However, it is interesting to note that while the relative odds of 
identifying node-positive disease increased over time, the overall proportion of node-positive 
cancers did not significantly increase in the population despite large increases in the number of 
lymph nodes evaluated.  
Finally, our results identify the continued inadequacy of lymph node evaluation, 
regardless of the role it may play in cancer staging or survival of patients. In a 2008 study of 
hospitals in the National Cancer Database, Bilimoria et al.28 found that over 45% of hospitals 
were still performing below guideline recommendations for adequate lymph node evaluation (≥12 
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nodes), more than 12 years after the first guideline was published. They suggested that although 
the proportion of hospitals consistently performing guideline recommended staging increased 
markedly from 1996-1997 to 2004-2005, the large number of US hospitals remaining non-
adherent with lymph node evaluation guidelines in 2004-2005 may indicate to some that this 
quality measure is not appropriate or less relevant for some cases. Our study builds on these 
findings and identifies that more than 25% of patients still had fewer than 12 lymph nodes 
evaluated in 2006-2008.  
 Although our study does provide further insight into the relationship between lymph 
node evaluation and survival in a population-based setting, we acknowledge several data-related 
limitations. First, SEER does not collect information on co-morbidities that may have affected the 
ability of the surgeon to remove an adequate tissue sample for lymph node evaluation. However, 
patients undergoing resection should have had an underlying level of general health to undergo 
the procedure. Additionally, we cannot differentiate between patients diagnosed through 
screening versus symptomatic presentation. However, others have shown that the proportion of 
patients diagnosed through screening has increased over time and is consistent with the shift 
toward earlier stages at diagnosis over time in our study.59-60 Finally, we are unable to determine 
the reason behind the extensiveness of lymph node evaluation for an individual cancer. 
Importantly, these results are more representative of cancers diagnosed in the US population 
because the data are not limited to elderly individuals and include all patients diagnosed with 
AJCC stage I-IV disease. 
             In conclusion, the number of lymph nodes evaluated for colon cancer markedly increased 
in the past two decades but was not associated with an overall shift toward higher staged cancers, 
questioning the upstaging mechanism as the primary basis for improved survival in patients with 
more lymph nodes evaluated.
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a P-value indicates significance of the Chi-square test unless otherwise noted.  
b Cochran-Armitage test for trend 
NOS: not otherwise specified 
Table 4: Assessment of Changes in Lymph Node Evaluation, Rates of Node Positivity, and Patient Characteristics Over Time (N=86,394) 
  1988-1990 1991-1993 1994-1996 1997-1999 2000-2002 2003-2005 2006-2008 P-
Valuea 
Number of Patients 11,200 11,517 11,492 12,545 13,209 13,121 13,310  
Lymph Node Evaluation over Time 
     
 
≥12 Lymph Nodes Evaluated 
(%) 
34.6 36.4 37.9 41.9 46.8 55.4 73.6 <0.001b 
Lymph Nodes Evaluated (%)        <0.001 
0 5.6 4.4 4.0 2.8 2.6 1.9 1.4  
1-8 44.3 44.0 42.1 38.7 33.9 27.0 13.1  
9-11 15.5 15.2 15.9 16.6 16.7 15.6 11.9  
12-15 14.5 15.2 15.5 16.8 16.9 18.6 21.0  
16-19 8.3 8.9 9.3 10.0 11.0 13.3 18.3  
20-29 8.5 9.2 9.8 10.6 13.1 15.8 23.3  
30-39 2.2 2.2 2.3 2.9 3.8 4.6 6.9  
≥40 1.0 1.0 1.1 1.6 2.0 3.1 4.1  
Proportion of Node Positive Cancers over Time 
     
 
Node Positive Cancers (%) 40.3 39.8 41.2 41.4 41.5 41.4 42.4 0.53b 
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a P-value indicates significance of the Chi-square test unless otherwise noted.  
b Cochran-Armitage test for trend 
NOS: not otherwise specified 
Table 4 (Continued): Assessment of Changes in Lymph Node Evaluation, Rates of Node Positivity, and Patient Characteristics Over Time (N=86,394) 
  1988-1990 1991-1993 1994-1996 1997-1999 2000-2002 2003-2005 2006-2008 P-
Valuea 
Patient Demographics, %  
     Age at Diagnosis    
<50 6.4  7.4  7.4  8.4 8.5  9.2  9.3  <0.001 
50-59 11.6  11.6  12.8  13.5  14.8  17.4  18.3   
60-69 26.1  24.4  23.6  22.2  22.2 21.9  23.7   
70-79 32.3  32.7  31.9  31.5  30.2  27.6  25.6   
≥80 23.6  23.9 24.3  24.4  24.3  23.9  23.1   
Race         
White 85.7  83.9  83.1 82.0  79.9  78.8  78.4  <0.001 
Black 8.4  9.3  9.1  9.5  10.2  10.9  11.3   
Other 15.9  6.8  7.8  8.5 9.9  10.3  10.4   
Sex         
Male 47.5  46.3  46.0  47.0  47.1  47.3 47.3  0.19 
Female 52.5  53.7  54.0  53.0  52.9  52.7  52.7   
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Table 4 (Continued): Assessment of Changes in Lymph Node Evaluation, Rates of Node Positivity, and Patient Characteristics Over Time (N=86,394) 
 
a P-value indicates significance of the Chi-square test unless otherwise noted.  
b Cochran-Armitage test for trend 
NOS: not otherwise specified 
  
  1988-1990 1991-1993 1994-1996 1997-1999 2000-2002 2003-2005 2006-2008 P-
Valuea 
Tumor Characteristics, % 
AJCC Stage         
1 16.0  17.6  17.9  19.8  22.0  23.7  24.6  <0.001 
2 37.4  36.9  35.9  34.5  32.8  31.4  31.2   
3 27.7  28.0  29.3  29.1  29.8  29.7  29.6   
4 18.9  17.5 16.9  16.6  15.4  15.2  14.6   
T-stage         
1 8.7  9.2  8.8 10.2  12.2  14.0  14.7  <0.001 
2 9.5  10.9  11.7  12.6  13.4  13.9  14.5   
3 49.9  49.6  50.6  50.5  49.6  54.8  57.8   
4 31.9  30.3  28.8  26.7  24.8  17.3  13.0   
Tumor Grade         
1/2 73.1  75.3  75.5  76.2  76.1  75.7  76.7  <0.001 
3/4 17.4  19.4  20.5  20.7  20.7  21.0  20.0   
Unknown 9.5  5.3  4.0  3.1  3.2 3.4  3.3   
Tumor Location         
Proximal 55.3  56.8  58.2  59.3  60.5  60.5  61.8  <0.001 
Distal 43.6  41.8 40.4  39.3 38.0  38.0  36.8   
Other 1.2  1.4  1.4  1.3  1.5  1.5  1.4   
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a P-value indicates significance of the Chi-square test unless otherwise noted.  
b Cochran-Armitage test for trend 
NOS: not otherwise specified 
 
 
 
 
Table 4 (Continued): Assessment of Changes in Lymph Node Evaluation, Rates of Node Positivity, and Patient Characteristics Over Time 
(N=86,394) 
  1988-1990 1991-1993 1994-1996 1997-1999 2000-2002 2003-2005 2006-2008 P-Valuea 
Initial Treatment, % 
SEER Type of Surgical 
Resection  
Partial Colectomy 
 
 
44.5 
 
 
41.6 
 
 
40.4 
 
 
43.5 
 
 
39.8 
 
 
42.2 
 
 
42.5 
<0.01 
Subtotal Colectomy/ 
Hemicolectomy 
46.2 50.1 51.2 50.6 55.7 55.3 55.1  
Total Colectomy         1.1 1.0 1.2 1.0 1.1 1.2 1.3  
Total Proctocolectomy 0.6 0.5 0.6 0.3 0.2 0.2 0.3  
Colectomy/ 
Coloproctectomy with en 
bloc resection of other 
organs 
Colectomy, NOS* 
7.2 
 
 
 
0.4 
6.6 
 
 
 
0.2 
6.3 
 
 
 
0.3 
4.3 
 
 
 
0.3 
2.8 
 
 
 
0.4 
0.7 
 
 
 
0.4 
0.4 
 
 
 
0.4 
 
Post-operative Radiation 
No 
Yes 
 
96.7 
3.3 
 
97.3 
2.7 
 
97.1 
2.9 
 
97.6 
2.4 
 
97.8 
2.2 
 
98.1 
1.9 
 
98.7 
1.3 
<0.01 
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Table 5: Relative Odds of Node Positivity among those with at Least One Lymph Node Evaluated, 
Multivariate Logistic Regression (N=83,671) 
 Odds Ratios [95% Confidence 
Interval] 
 Model 1 
N=83,671 
Model 2 
N=83,671 
≥12 Lymph Nodes Evaluated   
No Ref  
Yes 1.13 [1.09, 1.17]  
Lymph Nodes Evaluated   
1-8  Ref 
9-11  1.28 [1.23, 1.34] 
12-15  1.29 [1.24, 1.35] 
16-19  1.28 [1.21, 1.34] 
20-29  1.19 [1.13, 1.24] 
30-39  1.11 [1.02, 1.20] 
≥40  1.06 [0.96, 1.18] 
Age at Diagnosis    
<50 Ref Ref 
50-59 0.89 [0.84, 0.96] 0.89 [0.84, 0.95] 
60-69 0.78 [0.73, 0.83] 0.77 [0.73, 0.82] 
70-79 0.64 [0.60, 0.68] 0.63 [0.60, 0.67] 
≥80 0.52 [0.49, 0.56] 0.52 [0.49, 0.55] 
Race    
White Ref Ref 
Black 1.18 [1.12, 1.24] 1.17 [1.11, 1.24] 
Other 1.19 [1.11, 1.27] 1.19 [1.11, 1.27] 
Sex    
Male Ref Ref 
Female 0.97 [0.94, 1.00] 0.97 [0.94, 1.00] 
T-stage    
1 Ref Ref 
2 2.49 [2.27, 2.72] 2.46 [2.25, 2.69] 
3 7.98 [7.38, 8.63] 7.88 [7.29, 8.52] 
4 20.34 [18.74, 
22.09] 
20.15 [18.56, 
21.88] 
Tumor Grade   
1/2 Ref Ref 
3/4 2.06 [1.98, 2.14] 2.06 [1.98, 2.14] 
Unknown 0.99 [0.91, 1.08] 0.99 [0.91, 1.08] 
Tumor Location    
Proximal Ref Ref 
Distal 1.09 [1.05, 1.13] 1.09 [1.05, 1.14] 
Other 1.12 [0.99, 1.28] 1.13 [0.99, 1.29] 
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Bold indicates p<0.05 
Table 5 (Continued): Relative Odds of Node Positivity among those with at Least One Lymph 
Node Evaluated, Multivariate Logistic Regression (N=83,671) 
 
 Odds Ratios [95% Confidence 
Interval] 
 Model 1 
N=83,671 
Model 2 
N=83,671 
Type of Surgical Resection   
Partial Colectomy Ref Ref 
Subtotal Colectomy/ Hemicolectomy 0.98 [0.95, 1.02] 0.98 [0.94, 1.01] 
Total Colectomy 0.78 [0.67, 0.90] 0.79 [0.68, 0.92] 
Total Proctocolectomy 1.08 [0.84, 1.39] 1.10 [0.85, 1.41] 
Colectomy/Coloproctectomy with en bloc resection 
of other organs 
0.86 [0.78, 0.93] 0.85 [0.79, 0.93] 
Colectomy, NOS 0.85 [0.62, 1.17] 0.85 [0.62, 1.17] 
Year of Diagnosis   
1988-1990 Ref Ref 
1991-1993 0.97 [0.92, 1.03] 0.97 [0.92, 1.03] 
1994-1996 1.04 [0.98, 1.10] 1.04 [0.98, 1.10] 
1997-1999 1.06 [1.00, 1.12] 1.06 [1.00, 1.12] 
2000-2002 1.11 [1.05, 1.17] 1.10 [1.04, 1.17] 
2003-2005 1.19 [1.12, 1.26] 1.18 [1.12, 1.25] 
2006-2008 1.23 [1.16, 1.30] 1.22 [1.15, 1.2] 
Registry   
Iowa Ref Ref 
San-Francisco-Oakland 1.00 [0.95, 1.06] 1.00 [0.95, 1.06] 
Connecticut 1.06 [1.01, 1.12] 1.06 [1.00, 1.12] 
Metropolitan Detroit 1.08 [1.02, 1.14] 1.08 [1.02, 1.14] 
Hawaii 1.17 [1.07, 1.28] 1.17 [1.07, 1.28] 
New Mexico 1.12 [1.04, 1.21] 1.12 [1.04, 1.21] 
Seattle (Puget Sound) 1.04 [0.98, 1.10] 1.04 [0.98, 1.10] 
Utah 1.08 [0.99, 1.17] 1.09 [0.99, 1.18] 
Atlanta 1.16 [1.08, 1.24] 1.15 [1.08, 1.24] 
C-Index 0.74 0.74 
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Table 6a: Association between Lymph Node Evaluation and 5-Year Relative Hazard 
of Death, Cox Proportional Hazards Models+ 
  Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of Death 
All Patients 
N=86,394 
Unadjusted 5-Year 
Cumulative Mortality 
(%)* 
N=86,394 
Lymph Nodes Evaluated   
0 1.23 [1.17, 1.30] 55.4 
1-8 Ref 50.5 
9-11 0.87 [0.85, 0.90] 48.7 
12-15 0.83 [0.80, 0.85] 46.6 
16-19 0.74 [0.71, 0.77] 42.9 
20-29 0.73 [0.70, 0.76] 41.1 
30-39 0.66 [0.62, 0.71] 35.3 
≥40 0.64 [0.58, 0.70] 33.3 
Age at Diagnosis    
<50 Ref 34.7 
50-59 1.11 1.06, 1.18] 35.4 
60-69 1.37 [1.30, 1.43] 40.2 
70-79 1.90 [1.81, 1.99] 47.3 
≥80 3.30 [3.14, 3.46] 63.7 
Race    
White Ref 47.1 
Black 1.19 [1.15, 1.23] 52.1 
Other 0.89 [0.85, 0.94] 39.6 
Sex    
Male Ref 48.2 
Female 0.88 [0.86, 0.90] 45.8 
AJCC Stage    
1 Ref 22.0 
2 1.68 [1.61, 1.75] 35.9 
3 3.05 [2.93, 3.17] 51.6 
4 11.86 [11.39, 12.35] 92.9 
Tumor Grade   
1/2 Ref 44.0 
3/4 1.36 [1.33, 1.39] 59.6 
Unknown 1.00 [0.95, 1.06] 39 
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Table 6a (Continued): Association between Lymph Node Evaluation and 
5-Year Relative Hazard of Death, Cox Proportional Hazards Models+ 
 Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of Death 
All Patients 
N=86,394 
Unadjusted 5-
Year 
Cumulative 
Mortality (%)* 
N=86,394 
Tumor Location    
Proximal Ref 48.9 
Distal 0.85 [0.82, 0.87] 43.5 
Other 1.17 [1.08, 1.26] 59.1 
Type of Surgical Resection   
Partial Colectomy Ref 44.3 
Subtotal Colectomy/ 
Hemicolectomy 
0.99 [0.97, 1.03] 47.6 
Total Colectomy 1.29 [1.17, 1.42} 49.5 
Total Proctocolectomy 1.04 [0.89, 1.23] 52.6 
Colectomy/Coloproctectomy 
with en bloc resection of other 
organs 
1.01 [0.96, 1.06] 61.9 
Colectomy, NOS 1.30 [1.11, 1.51] 68.6 
Post-operative Radiation   
No Ref 46.6 
Yes 1.21 [1.14, 1.28] 59.8 
Year of Diagnosis   
1988-1990 Ref 53.1 
1991-1993 0.93 [0.90, 0.96] 50.6 
1994-1996 0.95 [0.91, 0.98] 50.2 
1997-1999 0.90 [0.87, 0.90] 48.0 
2000-2002 0.83 [0.80, 0.86] 44.1 
2003-2005 0.74 [0.72, 0.77] - 
2006-2008 0.73 [0.69, 0.77] - 
Registry   
Iowa Ref 47.2 
San-Francisco-Oakland 1.03 [0.99, 1.07] 47.3 
Connecticut 1.05 [1.01, 1.09] 48.3 
Metropolitan Detroit 1.09 [1.05, 1.13] 49.6 
Hawaii 1.05 [0.98, 1.12] 40.6 
New Mexico 1.08 [1.03, 1.14] 46.4 
Seattle (Puget Sound) 0.97 [0.93, 1.01] 44.5 
Utah 1.09 [1.03, 1.15] 46.1 
Atlanta 1.06 [1.02, 1.11] 46.7 
Bold indicates p<0.05 + Cox Proportional Hazards Models adjusted for all other factors 
listed. *Estimates from unadjusted Kaplan-Meier Survival curves. Note: As these are 
unadjusted mortality estimates across risk factors, the relative hazard ratios cannot be directly 
calculated by ratios of these values. 
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Table 6b: Association between Lymph Node Evaluation and 5-Year Relative Hazard 
of Death, Cox Proportional Hazards Models by Node-Positivity Status+ 
  Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of 
Death 
Node Negative Patients 
 (AJCC Stage I and II) 
N=47,162 
Adjusted Hazard Ratio  
[95% Confidence 
Interval] 
5-Year Relative Hazard of 
Death 
Node Positive Patients 
 (AJCC Stage III and IV) 
N=39,232 
Lymph Nodes Evaluated   
0 1.22 [1.11, 1.33] 1.23 [1.15, 1.33] 
1-8 Ref Ref 
9-11 0.83 [0.79, 0.88] 0.89 [0.86, 0.93] 
12-15 0.79 [0.75, 0.83] 0.85 [0.82, 0.88] 
16-19 0.69 [0.65, 0.74] 0.77 [0.74, 0.81] 
20-29 0.65 [0.61, 0.69] 0.77 [0.74, 0.81] 
30-39 0.54 [0.48, 0.62] 0.73 [0.67, 0.79] 
≥40 0.53 [0.44, 0.63] 0.70 [0.63, 0.78] 
Age at Diagnosis    
<50 Ref Ref 
50-59 1.48 [1.28, 1.71] 1.09 [1.03, 1.16] 
60-69 2.14 [1.88, 2.45] 1.29 [1.23, 1.36] 
70-79 3.77 [3.31, 4.29] 1.65 [1.57, 1.74] 
≥80 7.80 [6.85, 8.87] 2.52 [2.38, 2.65] 
Race    
White Ref Ref 
Black 1.36 [1.28, 1.45] 1.13 [1.08, 1.18] 
Other 0.86 [0.79, 0.95] 0.91 [0.85, 0.96] 
Sex    
Male Ref Ref 
Female 0.76 [0.73, 0.78] 0.95 [0.92, 0.97] 
AJCC Stage    
1 Ref - 
2 1.68 [1.62, 1.75] - 
3 - Ref 
4 - 3.96 [3.85, 4.07] 
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Table 6b (Continued): Association between Lymph Node Evaluation and 5-Year 
Relative Hazard of Death, Cox Proportional Hazards Models by Node-Positivity 
Status+ 
 
  Adjusted Hazard 
Ratio  
[95% Confidence 
Interval] 
5-Year Relative 
Hazard of Death 
Node Negative 
Patients 
 (AJCC Stage I and 
II) 
N=47,162 
Adjusted Hazard Ratio  
[95% Confidence 
Interval] 
5-Year Relative Hazard of 
Death 
Node Positive Patients 
 (AJCC Stage III and IV) 
N=39,232 
Tumor Grade   
1/2 Ref Ref 
3/4 1.15 [1.10, 1.21] 1.46 [1.42, 1.50] 
Unknown 0.92 [0.85, 1.00] 1.09 [1.01, 1.17] 
Tumor Location    
Proximal Ref Ref 
Distal 0.96 [0.92, 1.01] 0.78 [0.76, 0.86] 
Other 1.22 [1.05, 1.42] 1.16 [1.05, 1.26] 
Type of Surgical Resection   
Partial Colectomy Ref Ref 
Subtotal Colectomy/ 
Hemicolectomy 
1.02 [0.98, 1.07] 0.99 [0.95, 1.02] 
Total Colectomy 1.50 [1.29, 1.75} 1.21 [1.06, 1.37} 
Total Proctocolectomy 1.17 [0.87, 1.59] 1.00 [0.83, 1.22] 
Colectomy/Coloproctectomy with 
en bloc resection of other organs 
1.29 [1.17, 1.41] 0.91 [0.86, 0.96] 
Colectomy, NOS 1.20 [0.78, 1.87] 1.32 [1.13, 1.57] 
Post-operative Radiation   
No Ref Ref 
Yes 1.63 [1.45, 1.85] 1.10 [1.03, 1.18] 
 
Bold indicates p<0.05 
+ Cox Proportional Hazards Models adjusted for all other factors listed. 
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Table 6b (Continued): Association between Lymph Node Evaluation and 5-Year 
Relative Hazard of Death, Cox Proportional Hazards Models by Node-Positivity 
Status+ 
 
  Adjusted Hazard 
Ratio  
[95% Confidence 
Interval] 
5-Year Relative 
Hazard of Death 
Node Negative 
Patients 
 (AJCC Stage I and 
II) 
N=47,162 
Adjusted Hazard Ratio  
[95% Confidence 
Interval] 
5-Year Relative Hazard of 
Death 
Node Positive Patients 
 (AJCC Stage III and IV) 
N=39,232 
Year of Diagnosis   
1988-1990 Ref Ref 
1991-1993 0.98 [0.93, 1.05] 0.90 [0.86, 0.94] 
1994-1996 0.96 [0.91, 1.02] 0.94 [0.90, 0.98] 
1997-1999 0.95 [0.89, 1.01] 0.87 [0.84, 0.91] 
2000-2002 0.89 [0.83, 0.94] 0.79 [0.76, 0.83] 
2003-2005 0.85 [0.80, 0.91] 0.68 [0.65, 0.72] 
2006-2008 0.88 [0.81, 0.96] 0.66 [0.62, 0.70] 
Registry   
Iowa Ref Ref 
San-Francisco-Oakland 1.04 [0.98, 1.11] 1.01 [0.97, 1.06] 
Connecticut 1.12 [1.06, 1.19] 1.00 [0.96, 1.05] 
Metropolitan Detroit 1.16 [1.09, 1.24] 1.05 [0.99, 1.10] 
Hawaii 1.00 [0.89, 1.13] 1.06 [0.97, 1.14] 
New Mexico 1.12 [1.03, 1.23] 1.06 [0.99, 1.13] 
Seattle (Puget Sound) 0.98 [0.91, 1.04] 0.96 [0.95, 1.02] 
Utah 1.10 [1.00, 1.21] 1.08 [1.00, 1.06] 
Atlanta 1.18 [1.09, 1.28] 1.00 [0.95, 1.06] 
Bold indicates p<0.05 
+ Cox Proportional Hazards Models adjusted for all other factors listed.  
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Figure 2: Colon Cancer Lymph Node Evaluation Over Time (N=86, 394)
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Figure 3: Colon Cancer Lymph Node Positivity Over Time,
By T-Stage (N=86,394)
All T-stages
T1
T2
T3
T4
P=0.51
P=0.001
P=0.06
P<0.001
P<0.001
*
* Cochran-Armitage test for trend evaluating changes in lymph node positive cancer over time, overall and by T-stage.  2-sided p-values
Total Number of Patients
Total 11,200                     11,517                     11,492 12,545                      13,209                     13,121                    13,310
T1      972                         1,055                       1,022                        1,279                         1,611                      1,830                       1,958
T2 1,069                       1,265                       1,339                        1,576 1,773                      1,827                        1,926
T3    5,583                       5,713                       5,819                        6,331                         6,552                      7,190                        7,698                       
T4    3,576                       3,484                       3,312                        3,359 3,273                      2,274                        1,728
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Chapter 4: Quality of Care Along the Cancer Continuum: Does Receiving Adequate 
Lymph Node Evaluation for Colon Cancer Lead to More Comprehensive Post-
Surgical Care? 
  
 43 
 
 
Background: Among surgically treated patients with colon cancer, lower mortality has been 
demonstrated in those with ≥12 lymph nodes evaluated. We examined whether patients receiving 
adequate lymph node evaluation were also more likely to receive comprehensive post-surgical 
care, leading to lower mortality. 
 
Methods:  We used the 1992-2007 SEER-Medicare data to identify surgically-treated AJCC stage 
III colon cancer patients. We used chi-square analyses and logistic regression to evaluate the 
association between adequate (≥12) lymph node evaluation and receipt of post-surgical care 
(adjuvant chemotherapy, surveillance colonoscopy, computed tomography scans and 
carcinoembryonic testing) and Cox proportional hazards regression to evaluate 10-year overall 
mortality, adjusting for post-surgical care.  
 
Results: Among 17,906 surgically treated stage III colon cancer patients, individuals with 
adequate lymph node evaluation were no more likely to receive comprehensive post-surgical care 
than those with <12 nodes evaluated (p>0.05 for all). Adequate lymph node evaluation was 
associated with lower overall mortality (HR: 0.88; 95% CI [0.83-0.88]), but among 3-year 
survivors, the impact of adequate lymph node evaluation on lower mortality was diminished (HR: 
0.94; 95% CI [0.88-1.01]). However, receiving comprehensive post-surgical care was associated 
with continued lower mortality in 3-year survivors.  
 
Conclusions: Adequate lymph node evaluation for colon cancer was associated with lower 
mortality at diagnosis. However, after patients survived 3 years, the association between lymph 
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node evaluation and lower hazard of death was no longer significant; however, post-surgical care 
remained strongly associated with lower long-term mortality, indicating that post-surgical care 
may partially explain the relationship between lymph node evaluation and mortality.             
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Background 
With more than 100,000 new cases of colon cancer diagnosed in 2010,23 identifying 
pathways for improved treatment and survival is critical for reducing the burden of this disease on 
the population.2, 23 Several studies have demonstrated lower mortality among surgically treated 
colon cancer patients who have a more extensive lymph node evaluation.  As a result, several 
practice organizations now advocate for the surgical evaluation of 12 or more lymph nodes for 
acceptable staging of newly diagnosed colon cancer patients.11-14  One proposed mechanism to 
explain this association is that a more extensive lymph node evaluation reduces the risk of 
understaging, where a node-positive patient is incorrectly identified as node-negative. As a result, 
understaged patients may receive less aggressive adjuvant therapy or post-surgical care according 
to recommended guidelines.15, 22 However, several studies are now questioning this mechanism, 
demonstrating that more extensive lymph node evaluation has not necessarily resulted in a shift 
towards higher staged colon cancers.16-17 Rather, higher lymph node counts are associated with 
lower mortality regardless of whether patients are identified as having node-positive or node-
negative disease.18, 48  
While the underlying explanation for the node count-mortality relationship remains 
controversial, several groups have proposed that adequate lymph node evaluation may actually be 
a marker of more comprehensive, higher-quality care.16, 18, 22  Specifically, patients with more 
extensive lymph node evaluation may be more likely to receive guideline-recommended adjuvant 
therapy for their disease as well as more extensive follow-up and surveillance care compared with 
patients who receive inadequate lymph node evaluation. Current practice guidelines recommend 
that patients with AJCC stage III42 (i.e. lymph-node positive disease) receive adjuvant 
chemotherapy and a series of post-surgical surveillance exams in the period following treatment 
in order to monitor disease progression and control (Table 7).13, 42-46 Previous research has 
identified independent associations between adequate lymph node evaluation,6 adjuvant 
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therapy,13, 43-44 comprehensive post-surgical care13, 43-46 and lower mortality- however, no study 
has systematically evaluated how these combined interventions influence mortality. Our study 
further examines the relationship between adequate lymph node evaluation and mortality by 
evaluating whether adequate lymph node evaluation is associated with more comprehensive post-
surgical care for colon cancer patients, partially explaining the association between more 
extensive lymph node evaluation and lower mortality.  
Methods 
 
Data 
We used the 1992-2007 Surveillance, Epidemiology, and End Results (SEER) cancer 
registry data linked to Medicare enrollment records and utilization data (SEER-Medicare).61 
SEER currently collects and publishes cancer incidence and survival data from population-based 
cancer registries covering approximately 28% of the US population.62 The SEER-Medicare 
Patient Entitlement and Diagnosis Summary File (PEDSF) includes patient characteristics, 
primary tumor site, tumor stage and grade, first course of treatment (including surgery and 
irradiation), follow-up for vital status (survival), and number of lymph nodes pathologically 
examined.49  
Medicare provides comprehensive health care for approximately 97% of the U.S. 
population aged 65 or older.61 Cancer cases reported to SEER have been matched to the Medicare 
master enrollment file in order to facilitate population-based health services research. Medicare 
eligibility has been identified for 93% of people 65 or older identified by SEER.61 For Medicare 
enrollees who do not participate in a managed care plan, claims data are available through the 
Medicare Provider Analysis and Review (MedPAR) file, the National Claims History (NCH) file, 
and the Outpatient Standard Analytic File (SAF). Claims for hospitalizations and inpatient 
procedures are available in the MedPAR and NCH files, while office visits are captured through a 
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combination of NCH files for provider charges and Outpatient SAFs file for facility charges.  
This study was approved by the University of Minnesota Institutional Review Board. 
Patients  
We included 17,906 patients 66 years of age or older who were diagnosed with AJCC 
stage III adenocarcinoma of the colon from January 1, 1992, through December 31, 2007 and 
underwent radical resection for colon cancer (partial colectomy, hemicolectomy, total colectomy, 
total proctocolectomy, or coloproctotectomy) as the first course of treatment according to SEER 
and Medicare (Appendix 8). We excluded patients whose cancer was diagnosed by autopsy or 
was first cited on the death certificate; patients who underwent preoperative irradiation; patients 
with evidence of multiple resections within 6 months of diagnosis; patients with an unknown 
month of diagnosis; patients who were enrolled in a managed care organization any time from 6 
months prior to cancer diagnosis to 3 years after diagnosis (because Medicare files do not include 
insurance claims data on managed care enrollees); and patients with a previous history of cancer; 
and patients with an unknown number of nodes evaluated (Appendix 9).  
Lymph Node Evaluation 
SEER routinely records the number of nodes pathologically examined for each patient as 
well as the presence and number of positive lymph nodes (as a continuous measure). We 
categorized patients according to their receipt (yes/no) of adequate lymph node evaluation (at 
least 12 nodes evaluated). 
Post-Surgical Treatment  
Date of Surgical Resection 
We used the MedPAR date of surgical resection to determine receipt of recommended 
post-surgical care within the specified time-period after surgery for each guideline. We defined 
the date of surgical resection as the date corresponding to the radical resection codes in the 
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MedPAR file (Appendix 8). As invasive colon cancer requires an average hospital stay of 5-10 
days,63 the MedPAR file captures the majority of Medicare eligible fee-for-service patients 
undergoing colon cancer resection.64-65  
Receipt of Adjuvant Chemotherapy 
We classified patients as having received adjuvant chemotherapy (yes/no) if we found 
any claims-based evidence of chemotherapy administration or drug codes in the Medicare claims 
(NCH, Outpatient or MedPAR) within six months of diagnosis (see Appendix 10 for a complete 
list of codes). Based on previous studies evaluating chemotherapy in SEER-Medicare, we 
determined that one or more paid claims for chemotherapy was sufficient evidence to determine 
that a patient had undergone chemotherapy.66 However, we extended the observation period to 6 
months (2 months longer than guideline recommendations) to allow for potential coordinating 
efforts or post-surgical tests that might delay treatment initiation.  
Guideline Recommended Post-surgical Care 
Clinical practice guidelines from gastroenterology, oncology and surgery all advocate for 
routine follow-up and surveillance care after potentially curative resection for colon cancer.43-46 
While the exact timing and interval for recommended post-surgical care varies slightly by 
organization (Table 7), the majority of guidelines recommend some form of post-surgical 
surveillance and follow-up care in the 3 years after surgical treatment (Table 7). We selected 
three commonly recommended post-surgical guidelines for care after surgical resection 
(surveillance colonoscopy, computed tomography (CT) scan of the chest or abdomen, and 
carcinoembryonic antigen(CEA) testing) and searched for claims-based evidence of each in the 3 
years after diagnosis (yes/no).  
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Statistical Analysis 
 
We evaluated the unadjusted association between adequate lymph node evaluation (>12 
nodes examined), patient and tumor factors, and receipt of post-surgical care using chi-square 
tests. We then used logistic regression to identify the association between guideline-
recommended lymph node evaluation and receipt of 1) chemotherapy within 6 months of 
diagnosis and 2) post-surgical surveillance (surveillance colonoscopy, CT scan, and CEA testing), 
each within 3 years of surgical treatment.  Finally, we used Kaplan Meier methods and Cox 
proportional hazards modeling to evaluate the relationship between adequate lymph node 
evaluation and 10-year overall hazard of death. We evaluated predictors of mortality among all 
patients and those who survived at least 3 years, remaining eligible for care during the entire 
observation period.  All multivariate models used patients as the unit of analysis and were 
adjusted for age at diagnosis (66-69, 70-74, 75-79, 80-84, ≥85), race (White, Black, Other), sex, 
Charlson score67-68 (0, 1,  ≥2), tumor extent (T-stage53 I-IV), grade, tumor location (proximal, 
distal), year of diagnosis, and registry. 
We performed several sensitivity analyses to evaluate if the association between adequate 
lymph node evaluation, receipt of post-surgical care and mortality varied depending on modeling 
assumptions. Recognizing that the relationship between lymph node evaluation, receipt of post-
surgical care and mortality may vary by how evaluation and post-surgical care were defined, we 
evaluated this relationship using different cut-points for lymph node evaluation (0, 1-8, 9-11, 12-
15, 16-19, 20-29, 30-39, ≥40 nodes [Appendices 12a and b]) and the timeline for receipt of post-
surgical care (within 1 [Appendix 13] and 5 years [Appendix 14]). Additionally, we recognized 
that the relationship between lymph node evaluation, receipt of post-surgical care and mortality 
may be highly correlated or impact survival differently among patient risk-factors or subgroups. 
We therefore performed several sensitivity analyses evaluating potential interactions between 
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lymph node count, age at diagnosis, tumor grade, T-stage to identify whether the association 
between lymph nodes, post-surgical care and mortality varied by these factors [Appendices 15 
and 16]. Additionally, as the number of lymph nodes evaluated is highly correlated with the 
number of positive nodes identified [Appendix 17], we evaluated the association between lymph 
node evaluation and our outcomes adjusting for the number of positive nodes identified 
[Appendices 18 and 19]. Finally, we evaluated the association between lymph node evaluation, 
receipt of each type of post-surgical care and relative hazard of death separately in a series of 
models [Appendix 20]. Under all assumptions, our conclusions about the association between 
lymph node evaluation, receipt of post surgical care and relative hazard of death remained 
unchanged. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). All 
comparisons were pre-planned with p-values of ≤ 0.05 considered significant. 
Results 
Among 17,906 surgically treated stage III colon cancer patients, we found that younger 
(55.1% of 66-69 year olds vs. 50.4% of >80 year olds), white patients (53.6% White vs. 50.9% 
Black) and those with lower levels of comorbidites were all more likely to receive adequate 
lymph node-evaluation (Table 8). Further, patients with more extensive bowel penetration (e.g., 
more extensive T-stage) and high-grade disease were more likely to receive adequate lymph node 
evaluation (p<0.05 for all), indicating that healthier patients and those at a higher risk of node 
positivity were the same patients who received more extensive nodal evaluation.  
Receipt of Guideline-Recommended Post-Surgical Care 
We found higher unadjusted rates of adjuvant chemotherapy receipt (56.1% vs. 52.6%; 
≥12 LNs evaluated vs. < 12), CT scans (69.4% vs. 64.7%), CEA testing (74.5% vs. 68.8%) and 
surveillance colonoscopy (49.6% vs. 47.2%) among patients receiving adequate lymph node 
evaluation (Table 9). Limiting our evaluation to only those patients who survived to the end of 
the eligibility period for receipt of post-surgical care (e.g., 6-month and 3-year survivors), we 
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found no significant differences in the proportion of patients who underwent colonoscopy by 
level of lymph node evaluation. However, patients with adequate lymph node evaluation were 
still more likely to receive adjuvant chemotherapy, CT scans and CEA testing (p<0.05 for all). 
Adjusting for tumor and patient factors, patients who received adequate lymph node 
evaluation were also more likely to receive recommended post-surgical care (adjuvant 
chemotherapy, CEA testing, and colonoscopy), with the exception of CT scans (Tables 10a and 
10b). However, among patients who survived to the end of the eligibility period for post-surgical 
care, we found that individuals with adequate lymph node evaluation were no more likely to 
receive recommended post-surgical care than those with <12 nodes evaluated (p>0.05 for all). At 
the same time, several other patient and tumor factors remained consistent predictors of receiving 
post-surgical care including younger age, lower comorbidity score and lower T-stage at diagnosis 
(for receipt of CT scans and CEA testing only).  
10-Year Mortality 
Unadjusted Kaplan-Meier mortality estimates showed significantly lower 10-year overall 
mortality among patients who had adequate lymph node evaluation (Figure 4). Among 3-year 
survivors who were eligible for post-surgical care during the entire period, we continued to 
observe significantly lower unadjusted mortality among those with ≥12 lymph nodes evaluated 
(Figure 5). After adjusting for receipt of post-surgical care, we found that, at the time of surgical 
treatment, adequate lymph node evaluation was associated with lower relative hazard of death 
(adjusted hazard ratio (HR): 0.88; 95% Confidence Interval (0.85-0.91)  ≥12 LNs vs. <12 LNs 
evaluated). However, the association between lymph node evaluation and mortality lessened the 
longer patients survived after surgery (Table 11). Among 3-year survivors, adequate lymph node 
evaluation was no longer associated with significantly lower 10-year hazard of death (HR:0.94; 
95% CI (0.88-1.01), ≥12 LNs vs. <12 LNs evaluated). At the same time, in these 3-year 
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survivors, receiving recommended post-surgical care was still associated with significantly lower 
10-year hazard of death, with the exception of those receiving CT scans.  
We found a significant interaction between receipt of CT scans and comorbidity score at 
diagnosis indicating that the effect of receiving this care on mortality varied by how healthy 
patients were at diagnosis (Appendix 21). When stratified by comorbidity score, patients with low 
comorbidity scores (e.g., Charlson score ≤1) did have significantly lower mortality given they 
received a CT scan; however, sicker patients (e.g. Charlson comorbidity score ≥3) experienced 
higher mortality than those without the scan (See Appendix 22 for results). As Medicare claims 
do not provide a reason for the scan, these patients likely received CT scans due to the presence 
of post-operative symptoms or had other competing illnesses that may have contributed to less 
aggressive surgical care or adjuvant therapy. While adequate lymph node evaluation was not 
significantly associated with lower mortality after 3 years, other factors remained significantly 
associated with lower 10-year mortality including age at diagnosis, sex, T-stage, tumor location 
and comorbidity score.  
Discussion 
In our study of 17,906 surgically treated AJCC stage III colon cancer patients, we found 
that patients receiving adequate lymph node evaluation were initially more likely to receive 
recommended post-surgical care. However, for patients who survived at least 3 years after 
surgical treatment, we found patients who received adequate lymph node evaluation were no 
more likely to receive recommended post-surgical care. This suggests that high-quality surgical 
care does not necessarily lead to receipt of long-term follow-up care for colon cancer. Further, we 
found that while adequate lymph node evaluation was associated with lower 10-year hazard of 
death at the time of treatment. After patients survived 3 years, the association between lymph 
node evaluation and lower hazard of death was no longer significant; however, post-surgical care 
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remained strongly associated with lower long-term mortality indicating that post-surgical care 
may partially explain the relationship between lymph node evaluation and mortality. 
Our results are consistent with several studies that show that availability of high-quality 
medical care among patients diagnosed with chronic disease does not necessarily translate into 
the continued availability or use of recommended services. While the reasoning behind non-
adherence to recommended care for monitoring and control of chronic diseases is multi-factorial, 
several studies have demonstrated that insurance,69-70 socioeconomic and tumor factors70-71 and 
health-provider characteristics72 all play a role in the continued access and use of recommended 
services. In a small study of surgically treated colorectal cancer patients, Elston-Lafata et al. 
found significant differences by race, income  and tumor characteristics of patients who received 
CEA testing and colon examinations among insured patients in a managed care organization.73 
Our study builds upon these previous findings, identifying that access to high-quality surgical 
care and insurance coverage (i.e., Medicare) for recommended post-surgical care does not 
necessarily translate into higher use of those services. Therefore, future work should focus on the 
most effective system-wide interventions to encourage older, non-white patients and those with 
worse tumor prognosis (e.g., higher grade or T-stage) to undergo recommended post-surgical care 
as we demonstrate the important long-term benefits of this care on lower mortality across all 
patients.  
Our results also provide further insight into the evolving nature of risk factors as patients 
survive longer with their disease. Several studies have demonstrated the strong influence that 
lymph node evaluation has on lower mortality across patient demographic and tumor 
characteristics at the time of surgical treatment.6 In addition to lymph nodes, tumor characteristics 
such as higher T-stage and grade, as well as patient age and level of comorbidities predict long-
term mortality when patients are first treated.6 However, while tumor and demographic 
characteristics continue to provide prognostic information about long-term mortality after patients 
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survive several years with their disease, we found that lymph node evaluation is no longer 
associated with lower mortality among 3-year survivors, once adjusted for post-surgical care. At 
the same time, receiving recommended post-surgical care continues to provide long-term benefits 
of lower mortality among these 3-year survivors. These findings complement an emerging 
literature on the changing risk factors for long-term mortality as patients survive longer after their 
initial cancer diagnosis. Currently most clinicians use the American Joint Committee on Cancer 
(AJCC) staging system and prognostic modeling to develop survival estimates for patients after 
diagnosis, relying primarily on histological subtype, tumor grade, size, depth, and the presence of 
distant or nodal metastases at the time of diagnosis or treatment.8 However, previous studies of 
other cancers have demonstrated that the ability of some patient and tumor factors to predict 
survival may decrease over time, depending on patients’ current survival period.74-78 As a result, 
evaluating the changing impact of guideline recommended lymph node evaluation combined with 
post-surgical care as patients survive longer with their disease may provide more meaningful 
information to aid clinical decision management. Our study suggests that while lymph node 
evaluation does provide important initial information about mortality risk, the long-term benefits 
of more extensive lymph node evaluation may be due to the receipt of post-surgical care. 
Therefore, policy-makers and providers should examine best-practices for promoting continued 
use of recommended cancer treatment and post-surgical care after the initial survival period. 
While our study provides results from a large nationally-representative dataset, we 
acknowledge several data-related limitations. First, SEER-Medicare data are limited to patients 
over the age of 65 (66 to adjust for comorbidities in the year prior to diagnosis).  As a result, our 
conclusions may not be generalizable to younger colon cancer survivors. However, between 2003 
and 2007, the median age at diagnosis for cancer of the colon or rectum was 70 years of age.48 
Therefore, the analysis should capture a large portion of the population diagnosed with colon 
cancer in SEER geographic areas. Additionally, Medicare data represent administrative data 
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collected for billing purposes rather than research.  For this reason, our analysis was constructed 
to identify commonly billed procedures from a cohort of patients likely to have complete claims 
(i.e. surgical resection according to SEER, FFS in the six months prior to six months post 
diagnosis). Third, we are unable to distinguish between surveillance colonoscopy and symptom-
driven colonoscopy among patients. Finally, while health maintenance organizations may impact 
the receipt of specific types of post-surgical care, Medicare HMOs do not submit claims-based 
data forms that are released to researchers. Therefore, our analysis was limited to the fee-for-
service population and is generalizable to this specific subset of the Medicare population. 
However, SEER-Medicare allows for the analysis of a population-based set of cancer registries 
that includes patients from diverse backgrounds and practices from throughout the United States. 
Additionally, Medicare is the largest form of health insurance in the US population, making this 
study broadly applicable to a large population of elderly colon cancer patients. 
These findings provide several important implications for the use of lymph node 
evaluation as a quality-indicator for colon cancer care. First, our findings suggest that more 
extensive lymph node evaluation does provide important survival benefits in the initial years after 
surgical treatment. Considering that the evaluation of lymph nodes during surgical resection for 
colon cancer is not onerous, future guidelines should continue to promote evaluation as a 
combined approach to decrease long-term mortality in this population. Additionally, our findings 
should stimulate future work to identify other clinical and molecular markers that may present 
additional insight into the mechanism between lymph node evaluation and lower mortality 
directly after treatment. Finally, our findings point toward the continued need to encourage 
patients to maintain recommended surveillance and post-surgical care after their initial surgical 
treatment to maximize the benefits of high quality surgical care for colon cancer.  
In conclusion, we found that adequate lymph node evaluation is associated with lower 
mortality directly after surgical treatment, while post-surgical care is more strongly associated 
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with lower mortality after patients survive 3 years. However, patients who receive adequate 
lymph node evaluation are no more likely to receive recommended post-surgical care despite the 
combined long-term benefits lower mortality with this combined care approach. Policy-makers 
and providers should examine best-practices for promoting continued use of recommended cancer 
treatment and post-surgical care among cancer survivors and incorporation of these services into 
survivorship programs. 
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AJCC: American Joint Committee on Cancer 
 
Table 7: Adjuvant Therapy and Surveillance Guidelines for  AJCC Stage III42  Colon Cancer, by Recommending Organization 
     
Test National Comprehensive Cancer 
Network (NCCN)13, 44  
American Society for 
Clinical Oncology 
(ASCO)13, 43-44 
US Multi-Society Task Force 
on Colorectal Cancer 
(USMTF)45  
Gastrointestinal 
Consortium Panel46 
Chemotherapy Adjuvant chemotherapy within 4 
months for patients <80 years at 
diagnosis with AJCC Stage III (i.e. 
lymph node positive) colon cancer 
Adjuvant chemotherapy 
within 4 months for patients 
<80 years at diagnosis with 
AJCC Stage III (i.e. lymph 
node positive) colon cancer 
  
Surveillance 
Colonoscopy 
Within 1 year of diagnosis, unless 
no preoperative colonoscopy due to 
obstruction; then perform within 3-
6 months; If advance adenoma 
repeat in 1 year; If not advanced 
adenoma; repeat in 3 years; then 
every 5 years 
If complete preoperative 
colonoscopy, at 3 years; If 
results are normal, every 5 
years. 
If complete pre-operative 
colonoscopy performed, then 
at 1 year. If normal, repeat in 3 
years. If second colonoscopy 
is normal, repeat in 5 years. 
If no pre-operative 
colonoscopy, colonoscopy 
at 6 months after surgery; 
If normal, colonoscopy at 3 
years; If second 
colonoscopy is normal, 
repeat in 5 years. 
Computed tomography 
scan of the 
chest/abdomen 
Every year for 3 years for patients 
with high risk of recurrence (e.g. 
lymphatic invasion or poorly 
differentiated tumors) 
Every year for 3 years if 
stage III disease or high-risk 
stage II 
  
Carcinoembryonic 
antigen Test 
Every 3-6 months for 2 years; then 
every 6 months for a total of 5 years 
for T-stage 2 or higher tumors 
Every 3 months for at least 3 
years in patients with stage II 
or III disease 
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Table 8: Patient Tumor and Demographic Characteristics by Level of 
Lymph Node (LN) Evaluation for Colon Cancer, AJCC Stage III 
Patients (N=17,906 ) 
  
<12 LN 
(N=8,374) 
≥12 LN 
(N=9,532) 
Total 
N 
P-
Value 
Age      0.004 
66-69 44.9 (1,168) 55.1 (1,430) 2,598   
70-74 46.0 (1,807) 54.0 (2,119) 3,926   
75-79 46.3 (2,018) 53.7 (2,342) 4,360   
80-84 46.8 (1,737) 53.2 (1,971) 3,708   
≥85 49.6 (1,644) 50.4 (1,670) 3,314   
Race      0.01 
White 46.4 (7,067) 53.6 (8,150) 15,217   
Black 48.1 (674) 51.9 (726) 1,400   
Other/Unknown 49.1 (633) 50.9 (656) 1,289   
Sex      0.0004 
Male 48.4 (3,582) 51.6 (3,827) 7,409   
Female 45.7 (4,792) 54.3 (5,705) 10,497   
Charlson Comorbidity 
Score     
 
  
0 45.8 (5,118) 54.2 (6,060) 11,178 <0.001 
1 45.8 (1,463) 54.2 (1,730) 3,193   
2 49.5 (838) 50.5 (856) 1,694   
≥3 51.9 (955) 48.1 (886) 1,841   
T-Stage    <0.001 
1 64.4 (271) 35.6 (150) 421  
2 52.5 (758) 47.5 (686) 1,444  
3 45.6(5,737) 54.5 (6,859) 12,596  
4 46.7 (1,608) 53.3 (1,837) 3,445  
Tumor Location      <0.001 
Proximal Colon 42.3 (5,379) 57.7 (7,332) 12,711   
Distal Colon 57.7 (2,995) 42.4 (2,200) 5,195   
Grade      <0.001 
Well/Moderately 
Differentiated 47.9 (5,797) 52.1 (6,311) 
 
12,108   
Poorly/Undifferentiated 44.5 (2,577) 55.5 (3,221) 5,798   
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Table 9: Proportion of Stage III Colon Cancer Patients  Receiving Guideline-Recommended Care, by Level of Lymph Node Evaluation 
(N=17,906), % (N)* 
Recommended Care <12 LN (N=8,374) ≥12 LN (N=9,532) P-Value 
Adjuvant Chemotherapy       
Chemotherapy Receipt within 6 months of Diagnosis               
(all patients) 52.6 (4,406) 56.1 (5,350) p<0.001 
Chemotherapy Receipt within 6 months of Diagnosis                
(6-month survivors) 59.3 (4,232 of 7,141) 61.3 (5,171 of 8,440) p=0.01 
Surveillance Colonoscopy       
Colonoscopy within 3 years of Surgical Treatment                  
(all patients) 47.2 (3,956) 49.6 (4,729) p=0.002 
Colonoscopy within 3 years of Surgical Treatment                   
(3-year survivors) 69.8 (3,074 of 4,406) 68.7 (3,852 of 5,610) p=0.20 
Computed Tomography (CT) Scan       
CT Scan of the Chest or Abdomen within 3 years of 
Surgical Treatment                                                                                  
(all patients) 64.7 (5,420) 69.4 (6,661) p<0.001 
CT Scan of the Chest or Abdomen within 3 years of 
Surgical Treatment                                                                                  
(3-year survivors) 69.5 (3,064 of 4,406) 72.3 (4,058 of 5,610) p=0.002 
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Table 9 (Continued): Proportion of Stage III Colon Cancer Patients  Receiving Guideline-Recommended Care, by Level of Lymph Node 
Evaluation (N=17,906), % (N)* 
Recommended Care <12 LN (N=8,374) ≥12 LN (N=9,532) P-Value 
Carcinoembryonic Antigen (CEA) Test        
Any CEA Test within 3 years of Surgical Treatment                 
(all patients) 68.8 (5,757) 74.5 (7,101) p<0.001 
Any CEA Test within 3 years of Surgical Treatment                     
(3-year survivors) 85.1 (3,751 of 4,406) 88.2 (4,945 of 5,610) p<0.001 
*Chi-square test
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Table 10a: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon 
Cancer Patients*, Adjusted Odds Ratio (95% CI) 
 
 
Chemotherapy Receipt within 6 
Months of Diagnosis 
Colonoscopy within 3 Years of 
Surgical Treatment 
 
 All Patients 
(N=17,906) 
6 Month 
Survivors            
(N= 15, 581) 
 All Patients 
(N=17,906) 
3 Year 
Survivors 
(N=10,016) 
LNs Evaluated        
<12  Ref Ref Ref Ref 
≥12  1.09 (1.02, 1.17) 1.01 (0.94, 1.10) 1.12 (1.05, 1.20) 0.98 (0.89, 1.08) 
          
Age                      66-69 Ref Ref Ref Ref 
70-74 0.65 (0.58, 0.74) 0.68 (0.59, 0.78) 0.81 (0.73, 0.89) 0.88 (0.75, 1.05) 
75-79 0.38 (0.33, 0.42) 0.37 (0.33, 0.43) 0.59 (0.54, 0.66) 0.70 (0.60, 0.81) 
80-84 0.14 (0.12, 0.16) 0.13 (0.12, 0.15) 0.36 (0.32, 0.39) 0.39 (0.34, 0.46) 
≥85 0.03 (0.03, 0.04) 0.03 (0.03, 0.04) 0.15 (0.13, 0.17) 0.17 (0.15, 0.20) 
Sex                    Female Ref Ref Ref Ref 
Male 1.13 (1.05, 1.21) 1.18 (1.09, 1.27) 1.00 (0.94, 1.07) 1.03 (0.94, 1.13) 
Race                    White Ref Ref Ref Ref 
Black 0.51 (0.45, 0.59) 0.51 (0.44, 0.59) 0.69 (0.61, 0.78) 0.63 (0.53, 0.74) 
Other/Unknown 0.94 (0.81, 1.09) 0.86 (0.73, 1.01) 0.97 (0.85, 1.12) 0.82 (0.69, 0.98) 
Charlson Score         
0 Ref Ref Ref Ref 
1 0.76 (0.69, 0.83) 0.78 (0.71, 0.87) 0.83 (0.76, 0.90) 0.89 (0.79, 1.00) 
2 0.66 (0.59, 0.74) 0.68 (0.59, 0.77) 0.74 (0.66, 0.83) 0.88 (0.75, 1.04) 
≥3 0.36 (0.32, 0.41) 0.39 (0.35, 0.45) 0.48 (0.43, 0.54) 0.66 (0.56, 0.78) 
Tumor Location         
Proximal Ref Ref Ref Ref 
Distal 0.95 (0.88, 1.03) 0.97 (0.89, 1.05) 1.06 (0.98, 1.13) 0.94 (0.85, 1.04) 
Grade         
Well/Moderately 
Differentiated Ref Ref Ref Ref 
Poorly/Undifferentiated 0.99 (0.92, 1.07) 0.92 (0.85, 0.99) 1.26 (1.18, 1.35) 1.11 (1.00, 1.22) 
T-stage         
1 Ref Ref Ref Ref 
2 0.84 (0.65, 1.09) 0.88 (0.67, 1.16) 0.85 (0.67, 1.08) 0.99 (0.74, 1.32) 
3 0.68 (0.53, 0.86) 0.77 (0.60, 0.99) 0.53 (0.42, 0.65) 0.59 (0.42, 0.99) 
4 0.56 (0.44, 0.71) 0.72 (0.55, 0.93) 0.31 (0.24, 0.39) 0.64 (0.48, 0.85) 
C-Index 0.79 0.79 0.71 0.68 
* Also adjusted for registry and year of diagnosis 
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Table 10b: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon 
Cancer Patients*, Adjusted Odds Ratio (95% CI) 
 
 
 
Computed Tomography (CT) Scan 
of the Chest or Abdomen within 3 
Years of Surgical Treatment 
Carcinoembryonic Antigen (CEA) 
Test within 3 years of Surgical 
Treatment 
 
 All Patients 
(N=17,906) 
3 Year 
Survivors 
(N=10,016) 
 All Patients 
(N=17,906) 
3 Year 
Survivors 
(N=10,016) 
Lymph Nodes 
Evaluated       
<12  Ref Ref Ref Ref 
≥12  1.05 (0.98, 1.13) 0.96 (0.87, 1.05) 1.09 (1.02, 1.16) 1.12 (0.99, 1.27) 
          
Age                      66-69 Ref Ref Ref Ref 
70-74 0.81 (0.72, 0.92) 0.87 (0.75, 1.02) 0.89 (0.80, 0.99) 0.67 (0.52, 0.85) 
75-79 0.63 (0.56, 0.70) 0.68 (0.59, 0.79) 0.74 (0.67, 0.82) 0.52 (0.41, 0.66) 
80-84 0.42 (0.37, 0.47) 0.43 (0.37, 0.50) 0.46 (0.41, 0.51) 0.27 (0.22, 0.35) 
≥85 0.19 (0.17, 0.22) 0.21 (0.17, 0.25) 0.21 (0.19, 0.24) 0.10 (0.08, 0.13) 
Sex                    Female Ref Ref Ref Ref 
Male 0.98 (0.92, 1.05) 1.03 (0.94, 1.13) 1.07 (1.01, 1.14) 1.12 (0.98, 1.27) 
Race         
White Ref Ref Ref Ref 
Black 0.86 (0.76, 0.98) 0.85 (0.70, 1.02) 0.77 (0.68, 0.87) 0.67 (0.53, 0.85) 
Other/Unknown 1.17 ( 1.01, 1.35) 1.06 (0.87, 1.28) 1.12 (0.98, 1.29) 0.83 (0.64, 1.08) 
Charlson Score         
0 Ref Ref Ref Ref 
1 0.92 (0.84, 1.01) 1.09 (0.96, 1.24) 0.97 (0.89, 1.06) 1.06 (0.89, 1.26) 
2 0.95 (0.84, 1.06) 1.11 (0.93, 1.31) 0.99 (0.89, 1.11) 0.80 (0.65, 0.99) 
≥3 0.75 (0.67, 0.83) 1.13 (0.94, 1.37) 0.63 (0.56, 0.69) 0.52 (0.42, 0.64) 
Tumor Location         
Proximal Ref Ref Ref Ref 
Distal 0.89 (0.83, 0.96) 0.98 (0.88, 1.08) 0.94 (0.87, 1.01) 0.91 (0.79, 1.05) 
Grade         
Well/Moderately 
Differentiated Ref Ref Ref Ref 
Poorly/Undifferentiated 1.02 (0.95, 1.10) 1.06 (0.95, 1.17) 1.01 (0.95, 1.09) 0.99 (0.87, 1.14) 
T-stage         
1 Ref Ref Ref Ref 
2 0.98 (0.77, 1.26) 1.04 (0.78, 1.39) 0.92 (0.73, 1.16) 1.46 (0.99, 2.14) 
3 1.06 (0.85, 1.33) 1.12 (0.86, 1.45) 0.79 (0.65, 0.98) 1.24 (0.88, 1.74) 
4 1.00 (0.79, 1.27) 1.29 (0.97, 1.72) 0.72 (0.58, 0.89) 1.42 (0.98, 2.07) 
C-index 0.68 0.70 0.69 0.74 
* Also adjusted for registry and year of diagnosis 
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Table 11: Factors Associated with 10-Year Relative Hazard of Death Among AJCC Stage III Colon 
Cancer Patients, Cox Proportional Hazard Models, Hazard Ratio, 95% CI 
 All Patients (N=17,906) 3-Year Survivors (N=10, 016) 
  Model 1 Model 2 Model 3  Model 4 
Lymph Nodes 
Evaluated         
<12  Ref Ref Ref Ref 
≥12  0.86 (0.83, 0.89) 0.88 (0.85, 0.91) 0.94 (0.88, 0.99) 0.94 (0.88, 1.01) 
Guideline Recommended Post-Surgical Care     
Chemotherapy within 6 
months of diagnosis   0.82 (0.78, 0.86)   0.72 (0.67, 0.79) 
Colonoscopy within 3 
years of surgery   0.41 (0.39, 0.43)   0.68 (0.63, 0.73) 
CT scan within 3 years of 
surgery   1.3 (1.25, 1.36)   1.58 (1.47, 1.71) 
CEA within 3 years of 
surgery   0.49 (0.47, 0.52)   0.84 (0.76, 0.92) 
Patient and Tumor Factors       
Age         
66-69 Ref Ref Ref Ref 
70-74 1.26 (1.17, 1.35) 1.17 (1.09, 1.26) 1.36 (1.22, 1.52) 1.32 (1.19, 1.48) 
75-79 1.46 (1.36, 1.56) 1.25 (1.16, 1.33) 1.55 (1.39, 1.73) 1.48 (1.33, 1.65) 
80-84 1.92 (1.80, 2.05) 1.33 (1.23, 1.42) 2.16 (1.93, 2.42) 1.86 (1.65, 2.09) 
≥85 2.83 (2.65, 3.04) 1.47 (1.36, 1.58) 3.25 (2.88, 3.65) 2.46 (2.16, 2.79) 
Sex         
Female Ref Ref Ref Ref 
Male 1.14 (1.09, 1.18) 1.17 (1.12, 1.21) 1.33 (1.25, 1.42) 1.35 (1.26, 1.44) 
Race         
White Ref Ref Ref Ref 
Black 1.13 (1.06, 1.22) 0.99 (0.92, 1.06) 1.10 (0.97, 1.25) 1.02 (0.90, 1.16) 
Other/Unknown 0.87 (0.81, 0.95) 0.83 (0.76, 0.90) 0.88 (0.77, 1.01) 0.85 (0.74, 0.97) 
Charlson Comorbidity 
Score         
0 Ref Ref Ref Ref 
1 1.28 (1.22, 1.34) 1.25 (1.19, 1.31) 1.37 (1.26, 1.48) 1.33 (1.22, 1.45) 
2 1.33 (1.25, 1.42) 1.22 (1.14, 1.29) 1.42 (1.27, 1.48) 1.37 (1.23, 1.530 
≥3 1.89 (1.78, 1.99) 1.55 (1.46, 1.64) 2.09 (1.87, 2.34) 1.91 (1.71, 2.13) 
Tumor Location         
Proximal Ref Ref Ref Ref 
Distal 1.19 (1.15, 1.24) 1.18 (1.13, 1.22) 1.15 (1.07, 1.23) 1.14 (1.06, 1.22) 
Grade         
Well/Moderately 
Differentiated Ref Ref Ref Ref 
Poorly/Undifferentiated 0.97 (0.93, 1.01) 0.95 (0.91, 0.99) 0.96 (0.90, 1.04) 0.97 (0.90, 1.04) 
T-stage         
1 Ref Ref Ref Ref 
2 1.27 (1.07, 1.50) 1.31 (1.10, 1.55) 1.22 (0.96, 1.55) 1.25 (0.98, 1.60) 
3 1.97 (1.69, 2.31) 1.85 (1.58, 2.16) 1.61 (1.29, 2.00) 1.59 (1.27, 1.98) 
4 3.06 (2.61, 3.59) 2.66 (2.27, 3.12) 1.94 (1.53, 2.45) 1.88 (1.49, 2.37) 
* Also adjusted for registry and year of diagnosis   
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Figure 4: 10-Year Overall Mortality by Level of Lymph Node (LN) Evaluation            
 (N=17,906) 
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Figure 5: 10-Year Conditional Mortality by Level of Lymph Node (LN) Evaluation,                                               
3-Year Survivors (N=10,016) 
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Chapter 5: Hospital Characteristics Associated with Maintenance or Improvement of 
Guideline-recommended Lymph Node Evaluation for Colon Cancer 
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Background:  Over the past 20 years, several surgical practice organizations have recommended 
the identification of ≥12 lymph nodes from surgically treated colon cancer patients as an indicator 
of quality performance for adequate staging; however, studies suggest that significant variation 
exists among hospitals in their level of adherence to this recommendation. We examined hospital-
level factors that were associated with institutional improvement or maintenance of adequate 
lymph node evaluation after the introduction of surgical quality guidelines for colon cancer. 
Methods: Using the 1996-2007 SEER-Medicare linked data, we evaluated hospital 
characteristics associated with short- (1996-1998 vs. 1999-2001), medium- (1996-1998 vs. 2002-
2004), and long-term (1996-1998 vs. 2005-2005) improvement or maintenance of guideline-
recommended lymph node evaluation (≥12 lymph nodes evaluated) using chi-square tests and 
multivariate logistic regression, adjusting for patient case-mix.   
Results: We identified 228 hospitals that performed at least 6 colon cancer surgeries during each 
study period from 1996-2007. In the initial study period (1996-1998), 26.3% (n=60) of hospitals 
were performing guideline-recommended evaluation, increasing to 28.1% in 1999-2001, 44.7% in 
2002-2004, and 70.6% in 2005-2007. In multivariate analyses, a hospital’s prior guideline 
performance, teaching status and American College of Surgeon’s Oncology Group membership 
were significantly associated with short and medium-term improvement or maintenance of 
guideline-recommended lymph node evaluation; however, these factors were not associated with 
long-term performance. 
Conclusions: Over the 12 year period, there were significant improvements in hospital 
performance for guideline-recommended lymph node evaluation. Understanding where these 
improvements occur over time contributes to the debate over the optimal design of quality 
improvement programs.  
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Background            
   Several studies have identified an association between patients who have more lymph nodes 
evaluated during resection for colon cancer and improved survival.6 As a result of these studies, 
several organizations including the National Comprehensive Cancer Network and the American 
Society for Clinical Oncology have recommended the evaluation of 12 or more lymph nodes from 
resected colon cancer patients as an indicator of quality performance.13 The first guideline was 
issued in 1990 in the Working Party Report to the World Congress of Gastroenterology.  Since 
1997, the majority of surgical and oncology groups have recommended the evaluation of 12 or 
more lymph nodes during surgical resection for adequate staging. However, several studies have 
suggested that significant variation exists among hospitals in their level of adherence to this 
recommendation.21, 28 Previous single-institution and population-based studies have examined 
characteristics of providers who adhere to these guidelines,  finding  that after accounting for 
patient demographics and tumor characteristics, the majority of modifiable variation in guideline-
recommended evaluation occurs at the hospital level.79  
Various approaches have been advocated to address the issue of inadequate lymph node 
evaluation.  Increasingly, large payer organizations have begun to use lymph node evaluation 
guidelines to set pay-for-performance criterion. Specifically, the Centers for Medicare and 
Medicaid Services (CMS) has discussed the introduction of lymph node evaluation standards as a 
quality measure for pay-for-performance initiatives.79 However, concern has been raised that the 
use of these guidelines may divert resources away from resources more likely to result in 
improved patient outcomes, particularly when the exact threshold for lymph node evaluation to 
improve survival remains in contention.16, 22, 48 Additionally, studies have shown that 
underperforming hospitals are likely to remain so, despite concerted efforts to improve 
performance.80 Better understanding of hospital factors that contribute to improvement in 
guideline-recommended evaluation will provide policy-makers, administrators and payers with 
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information to guide future resource planning and areas to focus future quality improvement 
efforts. 
In this study, we address the issue of guideline compliance from an institutional 
perspective. Specifically, we examine hospital-level factors that are associated with institutional 
improvement or maintenance of guideline-recommended lymph node evaluation (median nodal 
evaluation ≥12) after the introduction of surgical quality guidelines for colon cancer in the 1990s.  
Methods 
 
Data 
For this hospital-level analysis examining patterns of improvement or maintenance of 
guideline-recommended lymph-node evaluation over time, we used the 1996-2007 Surveillance, 
Epidemiology, and End Results (SEER) cancer registry data linked to Medicare enrollment 
records and utilization data (SEER-Medicare).  SEER currently collects and publishes cancer 
incidence and survival data from population-based cancer registries covering approximately 26% 
of the US population.62 The SEER-Medicare Patient Entitlement and Diagnosis Summary File 
(PEDSF) includes patient characteristics, primary tumor site, tumor stage and grade, first course 
of treatment (including surgery and irradiation), follow-up for vital status, and number of lymph 
nodes pathologically examined.64  
Medicare provides comprehensive health care for about 97% of the U.S. population aged 
65 or older.64 Cancer cases reported to SEER have been matched to the Medicare master 
enrollment file, in order to facilitate population-based health services research. Medicare 
eligibility has been identified for 93% of people 65 or older identified by SEER.61, 64 For 
Medicare enrollees who do not participate in a managed care plan, claims data are available 
through the Medicare Provider Analysis and Review (MedPAR) file, the National Claims History 
(NCH) file, and the Outpatient SAF file. Claims for hospitalizations and inpatient procedures are 
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available in the MedPAR and NCH files, while office visits are captured through a combination 
of the NCH file for provider charges and the Outpatient SAF file for facility charges.61  
In addition to the SEER data and Medicare claims, NCI maintains a hospital file of all 
providers in the SEER-Medicare data. The file includes the number of Medicare-certified hospital 
beds, location (urban vs. rural), teaching status, hospital ownership, NCI cancer center status, and 
specialty group affiliation (e.g., American College of Surgeon’s Oncology Group [ACOSOG]). 
Most variables in the hospital file are abstracted from the Provider of Services (POS) and 
Healthcare Cost Report (HCRIS) files, which are maintained by the Center for Medicare and 
Medicaid Services (CMS).  NCI additionally collects information for the hospital file on specialty 
group affiliation (e.g, ACOSOG) and NCI cancer center status. The hospital file is available for 
the years 1996, 2000, 2001, 2002, 2003, 2005, 2006, and 2007.61  
Patients  
Included in our study were surgically treated patients ages 66 to 90 who were diagnosed 
with invasive, non-metastatic adenocarcinoma of the colon from January 1, 1996, through 
December 31, 2007.  We included only patients who underwent radical resection for colorectal 
cancer (partial colectomy, hemicolectomy, total colectomy, total proctocolectomy, or 
coloproctotectomy) as the first course of treatment according to SEER.  
Excluded from the study were patients with in situ, metastatic, or unstaged cancers; 
patients whose cancer was diagnosed by autopsy or first cited on the death certificate; patients 
who underwent preoperative irradiation; patients who were enrolled in a managed care 
organization any time from 6 months prior to cancer diagnosis (because Medicare files do not 
include insurance claims data on managed care enrollees) to 6 months post-diagnosis or death; 
patients with a previous history of cancer; and patients with an unknown number of nodes 
evaluated (See Appendix 23).  
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Hospitals  
In order to evaluate hospital-level factors associated with improvement or maintenance of 
guideline-recommended lymph node evaluation, we restricted the analysis to hospitals that treated 
patients during each of the time periods in our study (1996-1998, 1999-2001, 2002-2004 and 
2005-2007). Further, we restricted the analysis to only hospitals that performed at least 6 
surgeries during each of the 3 year study periods (i.e., performing on average at least two 
surgeries per year) to ensure the effect of hospital characteristics on performance was not due to 
the characteristics of a single patient or a small group of patients. Based on these criteria we 
identified a cohort of older colon cancer patients, in which each patient was linked with a single 
hospital during one of the time-periods included in the study.   
Identifying Hospital-Level Improvement or Maintenance of Guideline-Recommended Lymph 
Node Evaluation 
We evaluated short (1999-2001), medium (2002-2004) and long (2005-2007) term 
improvement or maintenance in guideline-recommended lymph node evaluation at the hospital 
level. We categorized hospitals as performing guideline-recommended lymph node evaluation if 
the median lymph node count during a study period was ≥12 (yes or no).  
Hospital-Level Measures 
 Hospital-level measures used in the analyses were identified from a combination of 
information included in the SEER-Medicare hospital file and Medicare claims. In order to 
identify initial factors associated with improvement or maintenance of guideline-recommended 
lymph node evaluation, we focused on hospital factors in the initial study period (1996-1998). 
Using the 1996 and 1998 Hospital files, we created a combined measure of teaching hospital 
status, based on presence of an American Medical Association-approved residency program 
(yes/no) in the hospital. We collapsed the categories of hospital ownership (non-profit, for-profit, 
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and government) and number of hospital beds (<200, 200-299, 300-399, >400) to allow for a 
sufficient number of hospitals in each category, while NCI cancer center status and ACOSOG 
membership were left unchanged. Finally, using the unique hospital identifier in the Medicare 
claims, we identified hospital volume of colorectal cancer radical resection procedures (in 
quartiles) for the initial study period (1996-1998) among patients included in our study.  
Statistical Analysis  
 
 We evaluated the unadjusted differences between demographic and hospital 
characteristics and guideline-recommended lymph node evaluation on a hospital level using chi-
square analyses. We then used multivariate logistic regression to evaluate the relationship 
between hospital characteristics and short, medium or long-term improvement or maintenance in 
guideline-recommended lymph node evaluation (yes vs. no) after adjusting for the case-mix of 
patients within facilities. Hospital characteristics included in the multivariate models included 
teaching hospital status/presence of an AMA approved residency program, hospital ownership, 
hospital volume, hospital location, and ACOSOG membership. Patient characteristics included 
the percentage of patients ≥80 years of age, the percentage of non-white patients, the percentage 
of male patients, the percentage of proximal tumors, the percentage of high grade tumors, the 
percentage of patients with a high Charlson score (≥3), and the percentage of high staged (AJCC 
Stage III) cancers treated by the hospital in each study period compared. For all statistical 
analyses, we used SAS software, version 9.2 (SAS Institute Inc., Cary, NC). P values ≤ 0.05 were 
considered statistically significant. 
Results 
 We identified 228 hospitals that surgically treated 24,926 patients for non-metastatic 
colon cancer between1996-2007 and performed at least 6 procedures in each study period. Over 
time, the distribution of patients in the hospital cohort shifted to patients more likely to be older at 
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diagnosis, non-white, and presenting with more advanced AJCC stage at diagnosis (Table 12). 
Further, over time, patients were more likely to be diagnosed with proximal tumors and have 
higher levels of comorbidity; however, no differences existed in patient sex or tumor grade over 
time. 
In the initial study period (1996-1998), 26.3% (n=60) of hospitals performed guideline-
recommended lymph node evaluation (Table 13). In this period, higher volume hospitals and 
those with ACOSOG affiliation were more likely to have an initial median lymph node count ≥12 
(Table 13). However, guideline recommended lymph node evaluation did not vary by teaching 
hospital status, hospital ownership, hospital volume, location, or NCI Cancer center status.  
Short-term Maintenance or Improvement (1999-2001) 
 Of the 228 hospitals included in our study, 28.1% (n=64/228) improved to or maintained 
guideline-recommended lymph node evaluation in the short-term. Of these 64 hospitals, 51.7% 
(n=31/60) of those performing guideline-recommended evaluation in the initial study period 
maintained guideline-recommended care, while 19.6% (n=33/168) of those performing below 
guidelines improved in the short-term (Figure 6). Multivariate analyses demonstrated that, after 
adjusting for patient case-mix, prior hospital guideline performance (OR (95% CI): 4.02 (1.92, 
8.41)) and ACOSOG membership (OR (95% CI): 3.39 (1.39, 8.30)), and urban location (OR 
(95% CI): 2.66 (1.12, 6.31)) were significantly associated with short-term improvement or 
maintenance of guideline-recommended lymph node evaluation (Table 14).  
Medium-term Maintenance or Improvement (2002-2004) 
 By 2002-2004, 44.7% (n=102/228) of hospitals had improved to or maintained guideline-
recommended lymph node evaluation. Of these hospitals, 65.0% (n=39/60) of those performing 
guideline-recommended evaluation in the initial study period maintained guideline-recommended 
care, while 37.5% (n=63/168) of those performing below guidelines improved in the medium-
term (Figure 6). Multivariate analyses demonstrated that, even in the medium-term, prior hospital 
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performance (OR (95% CI): 2.41 (1.17, 4.94)) and ACOSOG membership (OR (95% CI): 6.05 
(2.32, 15.77)) remained significantly associated with improvement or maintenance of guideline-
recommended lymph node evaluation (Table14). However, urban location was no longer a 
significant predictor of medium-term improvement or maintenance of guideline-recommended 
lymph node evaluation (OR (95% CI): 1.52 (0.76, 3.01)).  
Long-term Maintenance or Improvement (2005-2007) 
By 2005-2007, 70.6% (n=161/228) of hospitals had improved to or maintained guideline-
recommended lymph node evaluation. Of these hospitals, 80.0% (n=48/60) of those performing 
guideline-recommended evaluation in the initial study period maintained guideline-recommended 
care, while 67.3% (n=113/168) of those performing below guidelines improved in the long-term 
(Figure 6). However, after adjusting for patient case-mix, multivariate analyses identified no 
significant differences in improvement or maintenance of guideline-recommended lymph node 
evaluation across hospital characteristics (Table 14).  
While NCI cancer center status and hospital bed size were available to include in our 
multivariate models, we found each variable to be highly correlated with ACOSOG membership 
and hospital volume respectively, which diminished the significance of both sets of variables 
when all were included in our models. We, therefore, chose to remove these characteristics from 
our final multivariate models. 
Further, as the relationship between hospital characteristics and improvement or 
maintenance of guideline-recommended lymph node evaluation may change depending on how 
the characteristics or outcomes are defined, we performed several sensitivity analyses. First, we 
evaluated each of our multivariate models slightly varying the cut-point for guideline-
recommended evaluation (at 11 [Appendix 24] and 13 [Appendix 25] nodes respectively). 
Second, we removed non-significant factors from our analysis to see if this changed the 
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relationship between hospital characteristics and our outcomes. Under all analyses, our 
conclusions remained unchanged. 
Discussion 
In this study of 228 hospitals surgically treating non-metastatic colon cancer patients in 
the SEER-Medicare database, we found that prior hospital performance and ACOSOG specialty 
membership were most strongly associated with short- and medium-term improvement or 
maintenance of guideline-recommended lymph node evaluation after the introduction of surgical 
practice guidelines; however, these factors were no longer associated with guideline-
recommended lymph node evaluation in the long-term. Rather, by 2005-2007, more than half 
(70.6%, n=161) of all hospitals were performing at or above guideline-recommended care, which 
did not vary significantly across hospital characteristics. The results suggest that initially, 
rewarding hospitals for compliance with guidelines would primarily provide financial incentives 
to those who were already top performers while creating additional barriers to improvement 
among underperformers- as one of the factors most strongly associated with improvement or 
maintenance of guideline-recommended lymph node evaluation was guideline-recommended 
performance prior to guideline publication. 
Our results are consistent with previous work on the topic of guideline adherence. In a 
2011 study of colon cancer patients in the SEER-Medicare database, Nathan et al. examined 
patient and provider characteristics associated with guideline-level lymph node evaluation at any 
point in time.81 They found that the most modifiable variation in lymph node evaluation occurred 
at the hospital level. Specifically, they identified NCI cancer center designation and teaching 
status as significantly associated with adequate evaluation. They note, however, that these factors 
may in fact be proxies for hospital-level quality control measures, suggesting that these hospitals 
may have an overall higher baseline level of quality that can be generalized across the institution.  
Another study by Bilimoria et al.28 of surgically treated colon cancer patients in the National 
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Cancer database from 1996-2005 additionally found that NCI designated cancer centers, which 
may provide for more dedicated resources to track and focus on quality improvement efforts in 
this area, were more likely to comply with the 12 lymph node guideline.  Our study builds upon 
these findings, indicating that in addition to specialized hospitals (e.g., ACOSOG affiliated 
hospitals) the factor most strongly associated with improvement or maintenance of guideline-
recommended lymph node evaluation over time was a hospital’s prior performance.  
Our study also builds upon previous studies examining the implications of setting quality 
guidelines or pay-for-performance standards based on standard criteria across all providers. In a 
previous study of thirty-one separate pay for performance initiatives covering more than twenty 
million enrollees, Rosenthal et al.81 indicated that almost all of these programs created explicit 
winners and losers which would likely result in the redistribution of reimbursement from “low 
quality” to “high quality” providers.  Further, the study noted that while some “low quality” 
providers may be sufficiently motivated to make investments necessary to acquire financial 
incentives, many may find that the costs would exceed the modest financial benefits of doing so. 
Finally, despite good intentions, there are also concerns that implementing pay-for-performance 
programs may lead to patient selection against sicker or non-compliant patients. Another study by 
Rosenthal et al.80 examined the effectiveness of pay for performance initiatives in a large health 
plan using administrative reports of physician group quality.82 Using three process measures of 
clinical quality including cervical cancer screening, mammography and hemoglobin A testing, 
they found that for all measures, physician groups with baseline performance at or above the 
performance threshold for receipt of a bonus improved the least but garnered the largest share of 
the bonus payments. They concluded that paying clinicians to reach a common, fixed 
performance target may produce little gain in quality for the resources expended and primarily 
reward those with high baseline performance.  Finally, Mehrotra et al.83 conducted a study of 79 
physician groups in Massachusetts finding that practices with a pay for performance initiative 
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were more likely to have undertaken a quality improvement program to improve on that 
measure.83  However, the incentive and its associated improvement were modest at best. Further, 
physician group leaders said that incentives of five percent or more of revenue would be 
necessary to increase emphasis on specific quality improvement endeavors. As a result, the 
potential for undertaking quality improvement programs would be greater for large groups and 
integrated delivery systems that had more resources to support these efforts -- again biasing the 
receipt of financial incentives towards those traditionally performing well on quality indicators. 
Consistent with each of these findings, our study indicates that rewarding compliance with these 
surgical guidelines through financial incentives would primarily reward high achievers. Further, it 
would give the most money to those already performing well at the start, creating an environment 
of limited incentive for those performing in the bottom quartiles to improve. These findings are 
important in the context of future pay-for-performance initiatives and policy debates. 
While our study provides important implications for quality improvement initiatives, we 
acknowledge several data-related limitations. First, this study focused solely on patients 66 years 
and older residing in SEER areas. However, the majority of colon cancer cases are diagnosed in 
individuals 65 years and older and SEER now represents over 26% of the US population. 
Additionally, we were unable to determine if hospital-level node removal performance would 
vary if we were to include all patients undergoing colon cancer resection at the institution. It is 
unlikely that these estimates would vary greatly if these individuals were included, however, due 
to the small proportion of cases in this additional population. 
 Overall, our study provides important insights into the potential implications for future 
pay for performance initiatives in surgical oncology practice. Policy makers should consider 
programs aimed to improve performance of “low quality” performers rather than incentivize the 
status quo already provided by “high quality” institutions, as the institutions performing 
guideline-recommended lymph node evaluation prior to guideline publication were the same 
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hospitals most likely to remain adherent in each subsequent time period.  Additionally, 
researchers should focus on identifying the most important indicators of quality care that most 
influence mortality and comorbidity within this population. Learning from the evolution of 
quality improvement efforts over time will provide policy-makers, administrators and payers with 
information to guide future resource planning and areas to focus future quality improvement 
efforts. 
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Table 12: Patient Characteristics by Year of Diagnosis %(N) 
Patient Characteristics (N=24,926)  
Year of Diagnosis 1996-1998 1999-2001 2002-2004 2005-2007 P-Value 
Number of Patients 5,199 5,406 7,700 6,621   
Age                                         66-69 13.5 (703) 13.3 (717) 13.7 (1,057) 14.5 (959)  <0.001 
70-74 23.5 (1,220) 20.6 (1,114) 20.5 (1,579) 19.8 (1,313)   
75-79 24.6 (1,279) 24.9 (1,346) 24.6 (1,896) 22.6 (1,498)   
80-84 20.1 (1,046) 21.1 (1,143) 22.5 (1,728) 22.6 (1,497)   
≥85 18.3 (951) 20.1 (1,086) 18.7 (1,440) 20.5 (1,354)   
Race         <0.001 
White 89.1 (4,632) 87.9 (4,754) 85.6 (6,590) 84.6 (5,599)   
Black 5.4 (283) 5.5 (295) 6.6 (508) 6.6 (439)   
Other/Unknown 5.5 (284) 6.6 (357) 7.8 (602) 8.8 (583)   
Sex         0.26 
Female 58.8 (3,059) 59.5 (3,216) 57.8 (4,450) 58.7 (3,883)   
Male 41.2 (2,140) 40.5 (2,190) 42.2 (3,250) 41.4 (2,738)   
Charlson Comorbidity Score         <0.001 
0 65.0 (3,379) 63.2 (3,418) 60.0 (4,623) 58.1 (3,845)   
1 17.2 (896) 16.7 (902) 17.6 (1,354) 17.0 (1,130)   
2 8.7 (452) 9.7 (525) 10.7 (824) 11.4 (753)   
≥3 9.1 (472) 10.4 (561) 11.7 (899) 13.5 (893)   
AJCC Stage         <0.001 
I 23.5 (1,223) 27.2 (1,468) 27.9 (2,144) 26.9 (1,781)   
II 44.6 (2,319) 42.2 (2,284) 40.5 (3,120) 41.0 (2,712)   
III 31.9 (1,657)  30.6 (1,654) 31.6 (2,436) 32.1 (2,128)   
Tumor Location         <0.001 
Proximal Colon 67.9 (3,532) 71.2 (3,847) 71.3 (5,488) 72.6 (4,806)   
Distal Colon 32.1 (1,667) 28.8 (1,559) 28.7 (2,212) 27.4 (1,815)   
Grade         0.33 
Well/Moderately Differentiated 76.1 (3,958) 74.9(4,052) 76.1 (5,858) 75.2 (4,981)   
Poorly/Undifferentiated 23.9 (1,241) 25.1 (1,354) 23.9 (1,842) 24.8 (1,640)   
Lymph Node Evaluation           
≥12 Nodes 41.2 (2,141) 43.2 (2,336) 51.7 (3,979) 65.1 (4,312) <0.001 
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Table 13: Hospital Characteristics in the Initial Study Period (1996-1998), N (%) 
  All Hospitals 
Hospitals with Median LN 
count ≥12 
Hospitals with Median LN 
count <12 P-Value 
Total Number of Hospitals 228 60 168   
Organizational Characteristics         
Teaching Hospital                                   No 108 (47.4) 26 (43.3) 79 (47.0)  0.62 
Yes 120 (52.6) 34 (56.7) 89 (53.0)   
Hospital Ownership       0.67 
Non-Profit 161 (70.6) 45 (75.0) 116 (69.0)   
For-Profit 25 (11.0) 6 (10) 19 (11.3)   
Government 42 (18.4) 9 (15.0) 33 (19.7)   
Number of Hospital Beds       0.02 
<200 83 (36.4) 20 (33.3) 20 (37.5)   
200-299 67 (29.4) 12 (20) 55 (32.7)   
300-399 33 (14.5 8 (13.4) 25 (14.9)   
≥400 45 (19.7) 20 (33.3) 25 (14.9)   
Hospital Volume  1996-1998, in Quartiles       0.19 
1 (6-13  procedures) 60 (26.3) 14 (23.3) 46 (27.4)   
2 ( 14-21 procedures) 55 (24.1) 13 (21.7) 42 (25.0)   
3 (22-37 procedures) 60 (26.3) 12 (21.7) 47 (28.0)   
4 (≥38 procedures) 53 (23.3) 20 (33.3) 33 (19.6)   
Hospital Location       0.49 
Rural 49 (21.5) 11 (18.3) 38 (22.6)   
Urban 179 (78.5) 49 (81.7) 130 (77.4)   
ACOSOG Member  (Assessed in 2002)       0.03 
No 188 (82.5) 44 (73.3) 144 (85.7)   
Yes 40 (17.5) 16 (26.7) 24 (14.3)   
NCI Sponsored Cancer Center (in 2002)       0.77 
No 219 (96.1) 58 (96.7 ) 161 (95.8)   
Yes 9 (3.9) 2 (3.3) 7 (4.2)   
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Table 14: Hospital Factors associated with  Improvement or Maintenance of Adequate Lymph Node Evaluation (i.e. Median LN Evaluation ≥12),  
Odds Ratios (95% CI)* 
     Short-Term (1999-2001) Medium-Term (2002-2004) Long-Term (2005-2007) 
Initial Median LN Evaluation ≥12 (1996-
1998) Ref. Ref. Ref. 
Yes  4.021       (1.920, 8.419)* 2.406       (1.172, 4.943)* 1.547       (0.721, 3.317) 
Teaching Hospital       
No Ref. Ref. Ref. 
Yes 2.329       (1.027, 5.282)* 1.521       (0.767, 3.014) 1.604       (0.817, 3.150) 
Hospital Ownership       
Non-Profit Ref. Ref. Ref. 
For-Profit 0.987      (0.305, 3.187) 0.487       (0.167, 1.417) 0.967       (0.347, 2.694) 
Government 0.890       (0.311, 2.542) 1.954       (0.791, 4.829) 0.979       (0.420, 2.281) 
Hospital Volume 1996-1998  (Quartiles)       
1 (6-13  procedures) Ref. Ref. Ref. 
2 ( 14-21 procedures) 1.316       (0.463, 3.741) 2.404       (0.953, 6.063)  2.446       (1.026, 5.829) 
3 (22-37 procedures) 1.012       (0.353, 2.902) 2.151       (0.845, 5.475) 1.251       (0.536, 2.921) 
4 (≥38 procedures) 1.762       (0.576, 5.391) 1.261       (0.449, 3.542) 2.553       (0.892, 7.311) 
Hospital Location       
Rural Ref. Ref. Ref. 
Urban 1.293       (0.478, 3.496) 2.659       (1.122, 6.305) 1.406       (0.638, 3.098) 
ACOSOG Member    (Assessed in 2002)                                                
No Ref. Ref. Ref. 
Yes 3.393       (1.386, 8.308)* 6.048       (2.320, 15.766)*  2.496      (0.840, 7.414) 
C-Statistic 0.81 0.78 0.72 
*Also Adjusted for Hospital-Level patient factors including: % of patients ≥80 years of age, % non-white patients, % of male patients, % of proximal 
tumors, % of high grade tumors, % of patients with a high Charlson score (≥3), % high staged (AJCC Stage III) cancers treated by the hospital.  
    Number of Patients 10,605 12,899 11,820 
Number of Hospitals 228 228 228 
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Conclusions and Future Implications 
This 3-paper exam further examined the relationship between lymph node evaluation and 
improved survival for colon cancer. Colon cancer care provides an important opportunity to 
identify how providers and policymakers can achieve high quality outcomes in the context of 
quality guidelines. Previous studies have identified that among patients surgically treated for 
colon cancer, better survival has been demonstrated in those with more lymph nodes evaluated. 
Evaluated at the time of surgery, lymph node involvement (i.e. node positive disease) indicates 
advanced disease among colon cancer patients and a recommendation for adjuvant chemotherapy. 
Over the past 20 years, several practice organizations and consensus panels have identified the 
surgical evaluation of 12 or more lymph nodes as an important quality indicator for appropriate 
staging and treatment of newly diagnosed colon cancer patients. However, the exact mechanism 
behind more extensive lymph node evaluation and improved survival remains contentious. Using 
the Surveillance, Epidemiology and End Results (SEER) data and the SEER-Medicare data, 
which combines a set of cancer registry data linked to Medicare administrative claims, this 
research evaluated current gaps in knowledge surrounding the achievement and impact of lymph 
node quality guidelines for colon cancer care by l) further evaluating the mechanism between 
lymph node evaluation and survival 2) identifying whether high quality comprehensive care 
might account for this relationship and 3) understanding how to significantly improve guideline 
adherence among providers of colon cancer care. Overall, this research provides timely and 
significant evidence for future guideline recommendations surrounding the relative impact of 
lymph node evaluation for colon cancer care. 
Mechanisms of and Justification for Quality Guidelines 
Chapter 3 of this dissertation calls into question the presumed mechanism between higher 
lymph node evaluation and improved survival. Specifically, the results demonstrate that although 
lymph node evaluation has increased dramatically over the past 20 years, there has been no 
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subsequent increase in the number of lymph node positive cancers in the population. Further, 
although patients with a larger number of lymph nodes evaluated are only slightly more likely to 
be node-positive, these patients have significantly better survival than those with fewer nodes 
evaluated. This improved survival relationship among those with more lymph nodes evaluated 
was seen in patients with both node positive and node negative disease. Combined, these findings 
suggest that upstaging cannot be the mechanism underlying the relationship between increase 
lymph node evaluation and improved colon cancer survival. 
Overall, these findings may bring scrutiny to similar guidelines in other cancers. Future 
studies should continue to evaluate the presumed mechanism behind lymph node evaluation and 
improved outcomes in other cancers as well as the relationships between guideline adherence and 
improved outcomes more broadly. Such studies might evaluate the relationship between these 
guidelines, the types of individuals who adopt them and their resulting outcomes as a means to 
further identify why guidelines may lead to improved outcomes. Other avenues for research 
might further examine the biologic mechanisms between lymph node evaluation and improved 
survival in order to identify the molecular impact of lymph node removal on outcomes after 
cancer surgery. As healthcare resources are continually constrained and efforts emerge to 
promote efficient and effective means for healthcare utilization, these studies will become crucial 
for identifying guidelines that will likely have the largest impact on improved outcomes and 
promote use of targeted, effective healthcare utilization in the population.  
Quality of Care along the Cancer Continuum 
Chapter 4 further evaluates the mechanism between more extensive lymph node 
evaluation and improved survival by examining whether this relationship could be partially 
explained by more comprehensive post-surgical care. This second study demonstrates that among 
surgically treated AJCC stage III colon cancer patients in the SEER-Medicare linked data, 
individuals with adequate lymph node evaluation were no more likely to receive comprehensive 
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post-surgical care than those with <12 nodes evaluated. Further, while adequate lymph node 
evaluation for colon cancer was associated with lower mortality at diagnosis, after patients 
survived 3 years, the association between lymph node evaluation and lower hazard of death was 
no longer significant. However, post-surgical care remained strongly associated with lower long-
term mortality, indicating that post-surgical care may partially explain the relationship between 
lymph node evaluation and mortality.  
These findings present two key areas for future research. First, these findings suggest that 
receiving high quality surgical care does not necessarily lead to patients receiving more 
comprehensive follow-up care after this initial treatment. At the same time, receiving 
comprehensive post-surgical care was strongly associated with long-term survival, indicating that 
future efforts should focus on improving adherence to recommended surveillance and treatment 
after a patient is diagnosed. While many factors including patient preferences, insurance and 
knowledge about the most effective treatments can influence who ultimately receives post-
surgical care, identifying the reasons behind non-adherence will be important for designing 
effective survivorship programs for patients. Second, these findings bring further scrutiny to the 
proposed mechanism behind more extensive lymph node evaluation and improved survival, 
suggesting that receipt of post-surgical care after colon cancer surgery may partially explain this 
relationship. This relationship should be examined in other cancers, particularly those with high 
survivorship rates and a large post-treatment surveillance component after treatment. 
Understanding how to identify those patients who are less likely to receive high-quality care 
across the cancer continuum will be important for creating survivorship programs  that target 
individuals less likely to complete recommended adjuvant therapies or undergo post-treatment 
surveillance. 
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Adoption of Guidelines 
 Finally, Chapter 5 examined hospital-level factors that were associated with institutional 
improvement or maintenance of adequate lymph node evaluation after the introduction of surgical 
quality guidelines for colon cancer. The results showed that between 1996-2007, there were 
significant improvements in hospital performance for guideline-recommended lymph node 
evaluation. After adjusting for a hospital’s case-mix of colon cancer patients, a hospital’s prior 
guideline performance, teaching status and American College of Surgeon’s Oncology Group 
membership were all significantly associated with short and medium-term improvement or 
maintenance of guideline-recommended lymph node evaluation; however, these factors were not 
associated with long-term performance. The results suggest that initially, rewarding hospitals for 
compliance with guidelines would primarily provide financial incentives to those who were 
already top performers while creating additional barriers to improvement among 
underperformers.  
Overall, this research provides important insights into the potential implications for future 
pay-for-performance initiatives in surgical oncology practice, regardless of the utility of this 
particular guideline for lymph node evaluation. Policy makers should consider programs aimed to 
improve performance of “low quality” performers rather than incentivize the status quo already 
provided by “high quality” institutions.  Additionally, researchers should focus on identifying the 
most important indicators of quality care that most influence mortality and comorbidity within 
this population. Learning from the evolution of quality improvement efforts over time will 
provide policy-makers, administrators and payers with information to guide future resource 
planning and areas to focus future quality improvement efforts. 
In conclusion, understanding the mechanism that influences the node-survival 
relationship and leads to improved adherence to guideline recommended care will be instrumental 
in the design of future quality improvement programs. While lymph node evaluation alone may 
 87 
not drive improved survival, understanding the best combined mechanisms for influencing 
guideline recommended care will be important for identifying those components that significantly 
improve the quality of cancer care in the US.  
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Appendix 1: Interaction Analyses between the Level of Lymph Node Evaluation and Patient 
Factors, Logistic Regression Model Evaluating the Association between Lymph Node 
Evaluation and Relative Odds of Node Positivity 
 
The following sensitivity analyses evaluate the presence of a significant interaction between the 
level of lymph node evaluation a patient receives and other characteristics of those patients. 
Specifically, we assessed whether a significant interaction was present between the level of 
lymph node evaluation and patient age, race, sex, t-stage, and tumor grade. A significant 
interaction would indicate that the association between lymph node evaluation and odds of node-
positivity varied by one or multiple of these patient characteristics. We used the likelihood ratio 
test to evaluate the presence of a significant interaction in our models.84 The likelihood ratio test 
uses the ratio of the maximized value of the likelihood function for the interaction model (L1) 
over the maximized value of the likelihood function for the full model (L0). The likelihood test 
statistic equals:   
 
This log transformation of the likelihood function yields a chi-square statistic. We considered a p-
value for this chi-square statistic of <0.05 to be significant.   
 
For all interaction analyses, the Full model indicates a logistic regression model evaluating the 
association between lymph node evaluation and relative odds of node positivity, adjusting for 
patient age, race, sex, AJCC stage, tumor grade, tumor location, type of surgical resection, year of 
diagnosis and registry. 
 
LN Evaluation*Age Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 98773.27   
Full Model + Interaction 
term between LN 
Evaluation*age (L1) 
98736.03 24 0.05 
Difference 37.24   
 
 
LN Evaluation*Race Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 98773.27   
Full Model + Interaction 
term between LN 
Evaluation*Race (L1) 
98764.88 12 >0.25 
Difference 8.39   
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Appendix 1 (Continued): Interaction Analyses between the Level of Lymph Node 
Evaluation and Patient Factors, Logistic Regression Model Evaluating the Association 
between Lymph Node Evaluation and Relative Odds of Node Positivity 
 
 
LN Evaluation*Sex Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 98773.27   
Full Model + Interaction 
term between LN 
Evaluation*Sex (L1) 
98769.12 6 >0.25 
Difference 4.15   
 
LN Evaluation*T-stage Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 98773.27   
Full Model + Interaction 
term between LN 
Evaluation*T-stage (L1) 
98769.12 6 0.05 
Difference 4.15   
 
 
LN Evaluation*Tumor Grade Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 98773.27   
Full Model + Interaction 
term between LN 
Evaluation*Tumor 
Grade (L1) 
98764.34 12 >0.25 
Difference 8.93   
 
 
The interaction terms for LN Evaluation and race, sex and tumor grade were all non-significant. 
While the interaction terms for age*LN Evaluation and T-Stage*LN Evaluation were borderline 
significant, when stratified by these factors our conclusions about the association between more 
extensive lymph node evaluation and odds of node-positivity as well as survival remain 
unchanged (See appendices 2 and 3). 
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Appendix 2: Relative Odds of Node Positivity among those with at Least One Lymph Node Evaluated, Multivariate Logistic Regression                        
Stratified by T-Stage (N=83,671) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Also adjusted for age, race, sex, tumor grade, tumor location, type of surgical resection, year of diagnosis and registry.          
Bold indicates p<0.05 
 
In this sensitivity analysis, we find that the relative association between lymph node evaluation and odds of node positivity remains 
relatively stable when patients are stratified by T-stage. We continue to conclude that patients with more extensive lymph node 
evaluation are only slightly more likely to be node-positive than those with few nodes evaluated.  
 Odds Ratios [95% Confidence Interval] 
 T-Stage I 
N=8,788 
T-Stage II 
N=10,519 
T-Stage III 
N=44,380 
T-Stage IV 
N=19,984 
Lymph Nodes Evaluated     
1-8 Ref Ref Ref Ref 
9-11 1.13 [0.89, 1.42] 1.29 [1.12, 1.50] 1.28 [1.20, 1.36] 1.30 [1.19, 1.42] 
12-15 1.29 [1.02, 1.64] 1.19 [1.02, 1.39] 1.28 [1.21, 1.36] 1.36 [1.24, 1.48] 
16-19 1.53 [1.18, 1.99] 1.08 [0.91, 1.29] 1.25 [1.17, 1.34] 1.39 [1.25, 1.55] 
20-29 1.42 [1.08, 1.87] 1.18 [0.99, 1.40] 1.18 [1.10, 1.25] 1.19 [1.08, 1.33] 
30-39 1.69 [1.06, 2.67] 1.06 [0.79, 1.43] 1.11 [1.00, 1.23] 1.06 [0.89, 1.27] 
≥40 1.76 [1.01, 3.06] 1.71 [1.21, 2.40] 0.97 [0.85, 1.10] 1.09 [0.87, 1.37] 
C-Index 0.66 0.62 0.61 0.63 
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Appendix 2 (Continued): Relative Odds of Node Positivity among those with at Least One Lymph Node Evaluated, Multivariate Logistic Regression                        
Stratified by Age (N=83,671) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                       
 
* Also adjusted for age, race, sex, tumor grade, tumor location, type of surgical resection, year of diagnosis and registry. Bold indicates p<0.05 
 
In this sensitivity analysis, we find that the relative association between lymph node evaluation and odds of node positivity remains 
relatively stable when patients are stratified by age. We continue to conclude that patients with more extensive lymph node evaluation 
are only slightly more likely to be node-positive than those with few nodes evaluated for most patients- if at all. In the youngest 
patients, the relationship is not statistically significant, indicating that in younger patients, higher lymph node evaluation is not 
associated with statistically significant increases in the relative odds of node positivity.  
 Odds Ratios [95% Confidence Interval] 
 Age <50 
N=6,838 
Age 50-59 
N=12,083 
Age 60-69 
N=19,425 
Age 70-79 
N=25,203 
Age ≥80 
N=20,122 
Lymph Nodes Evaluated      
1-8 Ref Ref Ref Ref Ref 
9-11 1.41 [1.17, 1.69] 1.22 [1.08, 1.39] 1.33 [1.21, 1.46] 1.30 [1.20, 1.41] 1.22 [1.11, 1.34] 
12-15 1.19 [1.01, 1.41] 1.26 [1.12, 1.43] 1.27 [1.16, 1.40] 1.37 [1.26, 1.49] 1.25 [1.15, 1.37] 
16-19 1.30 [1.08, 1.57] 1.12 [0.98, 1.28] 1.17 [1.05, 1.30] 1.42 [1.29, 1.56] 1.32 [1.18, 1.46] 
20-29 1.20 [1.01, 1.43] 1.05 [0.93, 1.20] 1.22 [1.10, 1.36] 1.15 [1.04, 1.26] 1.30 [1.17, 1.44] 
30-39 1.06 [0.85, 1.33] 1.10 [0.90, 1.33] 1.03 [0.87, 1.22] 1.14 [0.98, 1.34] 1.21 [0.99, 1.48] 
≥40 1.01 [0.78, 1.30] 0.82 [0.64, 1.06] 1.10 [0.88, 1.38] 1.25 [0.99, 1.55] 1.21 [0.91, 1.59] 
C-Index 0.73 0.74 0.74 0.73 0.72 
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Appendix 3: Association between Lymph Node Evaluation and 5-Year Relative Hazard of Death, Cox Proportional Hazards Models,          
Stratified by T-Stage (N=86,394) 
 
 
 
* Also adjusted for age, race, sex, tumor grade, tumor location, AJCC Stage, type of surgical resection, post-operative radiation, year of diagnosis and registry. 
Bold indicates p<0.05. 
 
In this sensitivity analysis, we find that the relative association between lymph node evaluation and 5-year relative hazard of death 
remains relatively stable when patients are stratified by T-stage when compared to the findings in Tables 6a and 6b. We continue to 
conclude that patients with more extensive lymph node evaluation have a significantly lower 5-year relative hazard of death compared 
with those who have few nodes evaluated- with the exception of patient with T-1 disease who have no relative improvement in 
survival when more lymph nodes are evaluated. 
 Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of Death 
 
 T-Stage I 
N=8,788 
T-Stage II 
N=10,519 
T-Stage III 
N=44,380 
T-Stage IV 
N=19,984 
Lymph Nodes Evaluated     
0 1.26 [1.08, 1.49] 1.26 [1.01, 1.58] 1.31 [1.16, 1.49] 1.22[1.13, 1.31] 
1-8 Ref Ref Ref Ref 
9-11 1.07 [0.92, 1.26] 0.88 [0.78, 0.98] 0.83 [0.79, 0.87] 0.88 [0.84, 0.92] 
12-15 0.94 [0.79, 1.12] 0.93 [0.82, 1.04] 0.80 [0.76, 0.83] 0.81 [0.77, 0.84] 
16-19 0.86 [0.68, 1.07] 0.76 [0.65, 0.88] 0.71 [0.68, 0.75] 0.74 [0.70, 0.78] 
20-29 0.98 [0.79, 1.21] 0.78 [0.67, 0.91] 0.68 [0.65, 0.72] 0.75 [0.70, 0.79] 
30-39 0.74 [0.44, 1.25] 0.73 [0.54, 0.98] 0.63 [0.57, 0.69] 0.68 [0.61, 0.76] 
≥40 0.84 [0.48, 1.47] 0.56 [0.37, 0.84] 0.61 [0.53, 0.70] 0.63 [0.55, 0.72] 
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Appendix 3 (Continued): Association between Lymph Node Evaluation and 5-Year Relative Hazard of Death, Cox Proportional Hazards 
Models, Stratified by Age (N=86,394) 
 
 
 
* Also adjusted for age, race, sex, tumor grade, tumor location, AJCC Stage, type of surgical resection, post-operative radiation, year of diagnosis and registry. 
Bold indicates p<0.05. 
 
In this sensitivity analysis, we find that the relative association between lymph node evaluation and 5-year relative hazard of death 
remains relatively stable when patients are stratified by age when compared to the findings in Tables 6a and 6b. We continue to 
conclude that patients with more extensive lymph node evaluation have a significantly lower 5-year relative hazard of death compared 
with those who have few nodes evaluated. 
 Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of Death 
 
 Age <50 
N=7,032 
Age 50-59 
N=12,467 
Age 60-69 
N=20,182 
Age 70-79 
N=26,022 
Age ≥80 
N=20,691 
Lymph Nodes Evaluated      
0 1.15 [1.92, 1.43] 1.23 [1.05, 1.46] 1.46 [1.30, 1.64] 1.12 [1.01, 1.24] 1.21 [1.08, 1.34] 
1-8 Ref Ref Ref Ref Ref 
9-11 0.81 [0.71, 0.93] 0.89 [0.81, 0.98] 0.89 [0.83, 0.95] 0.86 [0.82, 0.91] 0.87 [0.82, 0.91] 
12-15 0.79 [0.70, 0.91] 0.82 [0.75, 0.91] 0.81 [0.75, 0.87] 0.84 [0.80, 0.88] 0.83 [0.78, 0.87] 
16-19 0.67 [0.57, 0.78] 0.73 [0.65, 0.82] 0.77 [0.71, 0.84] 0.71 [0.66, 0.76] 0.77 [0.72, 0.83] 
20-29 0.66 [0.57, 0.75] 0.70 [0.63, 0.78] 0.75 [0.69, 0.82] 0.71 [0.66, 0.76] 0.74 [0.70, 0.79] 
30-39 0.46 [0.37, 0.58] 0.67 [0.56, 0.81] 0.70 [0.60, 0.81] 0.66 [0.58, 0.75] 0.71 [0.62, 0.81] 
≥40 0.60 [0.47, 0.76] 0.51 [0.39, 0.67] 0.68 [0.56, 0.82] 0.64 [0.54, 0.77] 0.69 [0.57, 0.83] 
 102 
Appendix 4: Association between Lymph Node Evaluation and 5-Year Relative Hazard of Death, Cox Proportional Hazards Models, 
Alternative Category Groupings for Lymph Node Evaluation (N=86,394) 
 
 
 
 
 
* Also adjusted for age, race, sex, AJCC stage, tumor grade, tumor location, type of surgical resection, year of diagnosis and registry. Bold 
indicates p<0.05.  
 
In this sensitivity analysis, we conclude that receiving adequate lymph node evaluation is also associated with lower 5-year relative 
hazard of death, as were the models evaluating lymph node evaluation in smaller groupings (Tables 6a and 6b).  
 
  Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of Death 
All Patients 
N=86,394 
Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of 
Death 
Node Negative Patients 
 (AJCC Stage I and II) 
N=47,162 
Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of 
Death 
Node Positive Patients 
 (AJCC Stage III and IV) 
N=39,232 
≥12 Lymph Nodes Evaluated    
No Ref Ref Ref 
Yes 0.79 [0.77, 0.81] 0.73 [0.72, 0.76] 0.82 [0.80, 0.84] 
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Appendix 5: Removal of Non-Significant Factors from Multivariate Logistic Regression Models 
Assessing the Association Between More Extensive Lymph Node Evaluation and Relative Odds of 
Node Positivity (N=83,671) 
 
 
The following results are the Wald chi-square tests of significance for the logistic regression 
model when all factors believed to confound the association between more extensive lymph node 
evaluation and odds of node positivity are included in the model. Patient sex is borderline 
significant.  
 
Type 3 Analysis of Effects 
 
                                                    Wald 
                          Effect        DF    Chi-Square    Pr > ChiSq 
 
                          LN Eval        6      200.1665        <.0001 
                          Age            4      712.4850        <.0001 
                          Race           2       53.7257        <.0001 
                          Sex            1        3.6758        0.0552 
                          Tstage         3     8280.5233        <.0001 
                          Grade          2     1402.8943        <.0001 
                          Location       2       23.2200        <.0001 
                          Registry       8       38.8364        <.0001 
                          Surgery Type   5       24.6471        0.0002 
                          Year of Dx     6       87.3769        <.0001 
 
After removing patient sex from the multivariate model, we still conclude that more extensive 
lymph node evaluation is significantly associated with slightly higher relative odds of node 
positivity (see following page).  
 
       Type 3 Analysis of Effects with Age Removed 
 
                                                    Wald 
                          Effect        DF    Chi-Square    Pr > ChiSq 
 
                          LN Eval        6      199.4944        <.0001 
                          Age            4      734.6877        <.0001 
                          Race           2       52.9067        <.0001 
                          Tstage         3     8285.9164        <.0001 
                          Grade          2     1399.5994        <.0001 
                          Location       2       23.8327        <.0001 
                          Registry       8       38.9627        <.0001 
                          Surgery Type   5       25.6752        0.0001 
                          Year of Dx     6       87.4937        <.0001 
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Appendix 5 (Continued): Removal of Non-Significant Factors from Multivariate Logistic Regression 
Models Assessing the Association Between More Extensive Lymph Node Evaluation and Relative 
Odds of Node Positivity (N=83,671) 
 
 
* Also adjusted for age, race, T-stage, tumor grade, tumor location, type of surgical resection, 
year of diagnosis and registry. Bold indicates p<0.05.  
 Odds Ratios [95% Confidence Interval] 
 Model 1 with Sex 
Included 
N=83,671 
Model 2 with Sex 
Removed 
N=83,671 
Lymph Nodes Evaluated   
1-8 Ref Ref 
9-11 1.28 [1.23, 1.34] 1.28 [1.23, 1.34] 
12-15 1.29 [1.24, 1.35] 1.29 [1.23, 1.35] 
16-19 1.28 [1.21, 1.34] 1.27 [1.21, 1.34] 
20-29 1.19 [1.13, 1.24] 1.19 [1.13, 1.25] 
30-39 1.11 [1.02, 1.20] 1.11 [1.02, 1.20] 
≥40 1.06 [0.96, 1.18] 1.06 [0.95, 1.18] 
 105 
Appendix 6: Removal of Non-Significant Factors from Cox Proportional Hazards Models Assessing 
the Association Between More Extensive Lymph Node Evaluation and 5-year Relative Hazard of 
Death  
 
 
The following results are the Wald chi-square tests of significance for the Cox Proportional 
hazards regression model when all factors believed to confound the association between more 
extensive lymph node evaluation and 5-year relative hazard of death are included in the model. 
All factors are highly significant at p<0.05 and were kept in the final models. 
 
Model 1- All Patients (N=86,394) 
     
Type 3 Tests 
 
                                                    Wald 
                          Effect        DF    Chi-Square    Pr > ChiSq 
 
                          LN Eval        7      674.3048        <.0001 
                          Age            4     5722.1233        <.0001 
                          Race           2      114.7805        <.0001 
                          Sex            1      150.7413        <.0001 
                          AJCC Stage     3    24107.1559        <.0001 
                          Grade          2      620.9644        <.0001 
                          Location       2      187.1416        <.0001 
                          Registry       8       50.5949        <.0001 
                          Surgery Type   5       37.4303        <.0001 
                          Post-op Rad    1       39.0599        <.0001 
                          Year of Dx     6      354.0701        <.0001 
  
Model 2- Node-Positive Patients (N=39,232) 
 
         Type 3 Tests 
 
                                                    Wald 
                          Effect        DF    Chi-Square    Pr > ChiSq 
 
                          LN Eval        7      315.6796        <.0001 
                          Age            4     2153.2259        <.0001 
                          Race           2       43.3692        <.0001 
                          Sex            1       15.8060        <.0001 
                          AJCC Stage     1     9536.5600        <.0001 
                          Grade          2      677.6501        <.0001 
                          Location       2      241.0764        <.0001 
                          Registry       8       22.2093        0.0045 
                          Surgery Type   5       34.7383        <.0001 
                          Post-op Rad    1        7.1311        0.0076 
                          Year of Dx     6      388.9865        <.0001 
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Model 3- Node-Negative Patients (N=47,162) 
 
        Type 3 Tests 
 
                                                    Wald 
                          Effect        DF    Chi-Square    Pr > ChiSq 
 
                          LN Eval        7      386.5905        <.0001 
                          Age            4     3944.8655        <.0001 
                          Race           2      101.9057        <.0001 
                          Sex            1      238.8329        <.0001 
                          AJCC Stage     1      606.6609        <.0001 
                          Grade          2       38.9852        <.0001 
                          Location       2       10.3176        0.0057 
                          Registry       8       52.5623        <.0001 
                          Surgery Type   5       54.3556        <.0001 
                          Post-op Rad    1       63.8384        <.0001 
                          Year of Dx     6       36.8171        <.0001
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Appendix 7: Association between Lymph Node Evaluation and 5-Year Relative Hazard of Death, Cox Proportional Hazards Models, Adjusting 
for Tumor Extent using T-Stage Instead of AJCC Stage  
* Also adjusted for age, race, sex, tumor grade, tumor location, type of surgical resection, post-operative radiation, year of diagnosis and registry. 
Bold indicates p<0.05. In this sensitivity analysis, we find that the relative hazard of death as more lymph nodes are evaluated is comparable to 
Tables 6a and 6b, which adjust for AJCC stage instead of T-stage. These findings indicate that the association between lymph node evaluation and 
relative hazard of death is stable across measures for tumor extent. 
  Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of Death 
All Patients 
N=86,394 
Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of 
Death 
Node Negative Patients  
Adjusted Hazard Ratio  
[95% Confidence Interval] 
5-Year Relative Hazard of 
Death 
Node Positive Patients 
Lymph Nodes Evaluated    
0 1.35 [1.28, 1.43] 1.23 [1.12, 1.34] 1.57 [1.46, 1.69] 
1-8 Ref Ref Ref 
9-11 0.86 [0.79, 0.84] 0.82 [0.78, 0.86] 0.87 [0.83, 0.90] 
12-15 0.81 [0.71, 0.76] 0.78 [0.74, 0.83] 0.80 [0.77, 0.83] 
16-19 0.73 [0.71, 0.76] 0.69 [0.64, 0.74] 0.73 [0.70, 0.77] 
20-29 0.70 [0.67, 0.72] 0.64 [0.60, 0.69] 0.72 [0.68, 0.75] 
30-39 0.61 [0.57, 0.66] 0.54 [0.48, 0.62] 0.65 [0.60, 0.71] 
≥40 0.57 [0.52, 0.62] 0.52 [0.44, 0.62] 0.60 [0.54, 0.67] 
T-Stage    
I Ref. Ref. Ref. 
II 1.45 [1.37, 1.56] 1.29 [1.20, 1.38] 1.46 [1.22, 1.74] 
III 2.60 [2.46, 2.74] 1.83 [1.72, 1.95] 2.67 [2.28, 3.13] 
IV 7.72 [7.31, 8.16] 2.73 [2.53, 2.93] 7.42 [6.33, 8.70] 
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Appendix 8: Chapter 4 Patient Inclusion Criteria Codes, Colon Cohort (N=17,906) 
SEER Primary Site (ICD-O-3)   
C-180 Cecum 
C-182 Ascending Colon 
C-183 Hepatic Flexure 
C-184 Transverse Colon 
C-185 Splenic Flexure 
C-186 Descending Colon 
C-187 Sigmoid Colon 
SEER Tumor Histology (ICD-O-3)   
8140-8149, 8210-8219, 8220-8229, 
8260-8269, 8480-8489, 8570-8579 Adenocarcinomas 
AJCC (TNM) Stage, 6th Edition   
T1-4, N1-2, M0 Stage III 
SEER Surgery Codes- Radical Excision   
1992-1997   
30 Partial colectomy, but less than hemicolectomy 
40 
Hemicolectomy or greater (but less than total); right 
or left colectomy 
50 Total Colectomy 
60 Colectomy, NOS 
70 
Colectomy (subtotal, hemicolectomy or total) PLUS 
partial or total removal of other organs 
1998-2007   
30 Partial colectomy, but less than hemicolectomy 
40 
Hemicolectomy or greater (but less than total); right 
or left colectomy 
50 Total Colectomy 
60 Total Proctocolectomy 
70 
Colectomy or coloproctectomy WITH and en bloc 
resection of other organs: pelvic exenteration 
80 Colectomy, NOS 
Hospitalization data (MedPAR) ICD-9 Surgery Codes 
45.40-45.49 
Local excision or destruction of lesion or tissue of 
large intestine 
45.70-45.79 Open and partial excision of large intestine 
45.80-45.89 Total intra-abdominal colectomy 
ICD-O-3: International Classification of Diseases for Oncology, 3rd Revision; T=Extent of bowel 
wall penetration; N: Lymph Node Involvement; M: Metastases; ICD-9: International 
Classification of Diseases 9th Revision 
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Appendix 9: Final Cohort, Surgically Treated AJCC Stage III Colon Cancer 
Patients in SEER-Medicare between 1992-2007 (N=17,906) 
   
Inclusion Criteria Number Excluded Subtotal Remaining 
Clinical and Treatment Inclusion Criteria (SEER) 
Diagnosed with primary AJCC 
Stage IIII adenocarcinoma of the 
colon after age 66 between 1992-
2007 (Appendix 1)   30,891 
Not diagnosed by autopsy or death 
certificate  11 30,880 
Known Month of Diagnosis  26 30,854 
No pre-operative radiation  39 30,815 
Radical Excision Performed, 
according to SEER (Appendix 1)  203 30,612 
Known number of lymph nodes 
surgically evaluated  911 29,701 
Medicare Enrollment Inclusion Criteria 
No HMO enrollment six months 
prior to 3 years post diagnosis   7,684 22,017 
Enrolled in Medicare Part A + B six 
months prior to 3 years post 
diagnosis  1,781 20,236 
Treatment Inclusion Criteria (Medicare Claims-based Evidence) 
Hospitalization record for radical 
excision of the colon within six 
months of diagnosis  1,547 
18,689 
 
Only one Hospitalization record for 
radical excision within six months 
of diagnosis  783 17,906 
Final Cohort    17,906 
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Appendix 10: Chemotherapy Administration and Drug Codes Used to Identify 
Chemotherapy Receipt, by Type of Medicare File 
 
MedPAR 
Files 
Outpatient 
Files 
National 
Claims History 
(NCH) Files 
Durable Medical 
Equipment Files (DME) 
ICD-9 
Diagnosis 
Codes 
V58.1, 
V58.11, 
V58.12, 
V66.2, 
V67.2 
V58.1, V58.11, 
V58.12, V66.2, 
V67.2 
  
ICD-9 
Procedure 
Codes 
99.25 99.25 
  
CPT 
Procedure 
Codes 
(HCPCS) 
 
Administration: 
36260, 95990-
95991, 96400-
96549, Q0083-
Q0085, G0355-
G0362; Agents: 
C1167, C9127, 
C9414, C9425, 
C9427, C9431, 
C9432, C9440, 
C9205, C9214, 
C9215, C9257, 
C9418, E0782-
E0786, G0355-
G0362, J0207, 
J0640-J0641, 
J1190, J8520-
J8521, J8530, 
J8650, J8565, 
J8600, J8700, 
J8999, J9000-
J9999, Q2024, 
S0177 
Administration: 
36260, 95990-
95991, 96400-
96549, Q0083-
Q0085, G0355-
G0362; Agents: 
C1167, C9127, 
C9414, C9425, 
C9427, C9431, 
C9432, C9440, 
C9205, C9214, 
C9215, C9257, 
C9418, E0782-
E0786, G0355-
G0362, J0207, 
J0640-J0641, 
J1190, J8520-
J8521, J8530, 
J8650, J8565, 
J8600, J8700, 
J8999, J9000-
J9999, Q2024, 
S0177 
 
Revenue 
Center 
Codes 
 0331, 0332   
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Appendix 10 (continued): Chemotherapy Administration and Drug Codes 
  
MedPAR 
Files 
Outpatient 
Files 
National Claims 
History (NCH) 
Files 
Durable Medical Equipment 
Files (DME) 
NDC 
Codes 
      
4110013, 4110016, 4110020, 
4110022, 4110051, 4110113, 
4110116, 4110150, 4110151, 
53808041101, 54868414301-
03, 54868526001-09, 
17101050301-02, 
17101050401, 00179165270-
72, 6049117001, 6049117028, 
15050301,  378326694, 
55567005002, 55361163904, 
57423000104, 51079096501, 
51079096505, 15309145, 
85125901, 00085300101-02, 
00085300401-02, 
00085125201-02, 
00085151901-02, 
00085133601-02, 
00085142501-02, 
00085143001-02, 85141701, 
54868535400, 54868414202-
06, 54868534801, 
53922151901-02, 
53922136601-02, 
53922300401-02, 
53922141701, 53922143001-
02, 53922142501-02, 
11326124801-02, 
11326124401-02, 
11326125901-02, 
11326125201-02, 
51129309901,02, 
17088005001, 17088003101, 
17088004901, 66828003001, 
00078040105,34, 78043815,  
54868542700-03, 
54868528900-04 
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Appendix 11: Diagnosis and Procedure Codes Used to Determine Receipt of Post-Surgical Care, by Type of Medicare File 
Source 
ICD-9 Procedure 
Codes ICD-9 Diagnosis Codes CPT Procedure Codes 
Carcinoembyonic Antigen  (CEA) 
test       
MedPAR Files   795.81   
Outpatient Files   795.81 82378 
National Claims History (NCH) Files     82378 
Computed tomography (CT) scan 
of the chest and abdomen       
MedPAR Files 87.41, 88.01     
Outpatient Files 87.41, 88.01   
74150, 74160, 74170, 71250, 71260, 
71270 
National Claims History (NCH) Files     
74150, 74160, 74170, 71250, 71260, 
71270 
Colonoscopy       
MedPAR Files 
45.23, 45.25, 45.42, 
45.43 V76.51   
Outpatient Files 
45.23, 45.25, 45.42, 
45.43 V76.51 
G0105, G0121, 45378, 45379, 45381, 
45382, 45383, 45384, 45385, 45386, 
45387, 45391,  44388, 44389, 44390, 
44391, 44392, 44393, 44394, 44397 
National Claims History (NCH) Files     
G0105, G0121, 45378, 45379, 45381, 
45382, 45383, 45384, 45385, 45386, 
45387, 45391,  44388, 44389, 44390, 
44391, 44392, 44393, 44394, 44397 
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Appendix 12a: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon Cancer Patients, Alternate Category Groupings for 
Lymph Node Evaluation*, Adjusted Odds Ratio (95% CI) 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, year of diagnosis and registry. Bold indicates p<0.05.  
 Chemotherapy Receipt within 6 Months 
of Diagnosis 
Colonoscopy within 3 Years of Surgical 
Treatment 
  All Patients 
(N=17,906) 
6 Month Survivors            
(N= 15, 581) 
 All Patients 
(N=17,906) 
6 Month Survivors            
(N= 15, 581) 
Lymph Nodes Evaluated     
0 0.39 [0.16, 0.93] 0.46 [0.18, 1.25] 0.63 [0.27, 1.49] 0.62 [0.20, 1.88] 
1-8 Ref Ref Ref Ref 
9-11 1.13 [1.02, 1.26] 1.11 [0.99, 1.25] 1.12 [1.02, 1.24] 1.00 [0.87, 1.15] 
12-15 1.09 [0.99, 1.21] 1.03 [0.92, 1.15] 1.12 [1.02, 1.23] 1.00 [0.87, 1.14] 
16-19 1.15 [1.03, 1.30] 1.06 [0.94, 1.20] 1.22 [1.09, 1.35] 0.99 [0.87, 1.14] 
20-29 1.21 [1.08, 1.36] 1.10 [0.97, 1.25] 1.19 [1.07, 1.32] 0.96 [0.83, 1.11] 
30-39 1.24 [1.01, 1.51] 1.11 [0.89, 1.38] 1.32 [1.10, 1.58] 1.07 [0.84, 1.39] 
≥40 1.01 [0.77, 1.33] 0.87 [0.65, 1.17] 1.09 [0.85, 1.39] 0.73 [0.53, 1.01] 
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Appendix 12b: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon Cancer Patients Alternate Category Groupings for 
Lymph Node Evaluation*, Adjusted Odds Ratio (95% CI) 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, year of diagnosis and registry. Bold indicates p<0.05.  
In this sensitivity analysis breaking the level of lymph node evaluation out into smaller groups, we continue to find that at the time of diagnosis, 
patients who received adequate lymph node evaluation were also more likely to receive recommended post-surgical care (adjuvant chemotherapy, 
CEA testing, and colonoscopy), with the exception CT scans. However, among patients who survived to the end of the eligibility period for post-
surgical care, we found that individuals with adequate lymph node evaluation were no more likely to receive recommended post-surgical care than 
those with <12 nodes evaluated (p>0.05 for all). 
 
 Computed Tomography (CT) Scan of the 
Chest or Abdomen within 3 Years of 
Surgical Treatment 
Carcinoembryonic Antigen (CEA) Test within 
3 years of Surgical Treatment 
  All Patients 
(N=17,906) 
3 Year Survivors 
(N=10,016) 
 All Patients 
(N=17,906) 
3 Year Survivors 
(N=10,016) 
Lymph Nodes Evaluated     
0 0.34 [0.15, 0.77] 0.44 [0.14, 1.40] 0.54 [0.24, 1.19] 0.46 [0.13, 1.61] 
1-8 Ref Ref Ref Ref 
9-11 0.97 [0.88, 1.07] 0.88 [0.77, 1.02] 1.21 [1.09, 1.34] 1.06 [0.89, 1.28] 
12-15 1.04 [0.95, 1.15] 0.95 [0.83, 1.09] 1.19 [1.08, 1.32] 1.11 [0.93, 1.33] 
16-19 1.07 [0.96, 1.20] 0.94 [0.81, 1.10] 1.33 [1.18, 1.50] 1.06 [0.87, 1.30] 
20-29 0.98 [0.89, 1.10] 0.80 [0.69, 0.93] 1.35 [1.19, 1.52] 1.15 [0.94, 1.41] 
30-39 1.16 [0.95, 1.41] 1.08 [0.83, 1.41] 1.70 [1.37, 2.13] 1.74 [1.15, 2.62] 
≥40 0.89 [0.69, 1.17] 0.78 [0.55, 1.10] 1.52 [1.12, 2.07] 1.64 [0.92, 2.92] 
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Appendix 13a: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon Cancer Patients, Alternate Timing for Receipt of 
Post-Surgical Care (Within 1 Year of Surgery)*, Adjusted Odds Ratio (95% CI) 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, year of diagnosis and registry. Bold indicates p<0.05.  
 
 
 Chemotherapy Receipt within 12 Months 
of Diagnosis 
Colonoscopy within 12 months of Surgical 
Treatment 
  All Patients 
(N=17,906) 
12 Month Survivors            
(N= 15, 581) 
 All Patients 
(N=17,906) 
12 Month Survivors            
(N= 15, 581) 
Lymph Nodes Evaluated     
<12 Ref Ref Ref Ref 
≥12 1.07 [1.00, 1.15] 0.99 [0.91, 1.07] 1.11 [1.04, 1.20] 1.06 [0.97, 1.15] 
Chemotherapy Receipt within 1 Year of 
Diagnosi  
C lonoscopy within 1 Year of Surgical 
1 Year Survi ors            1 Year Survi ors            
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Appendix 13b: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon Cancer Patients, Alternate Timing for Receipt of 
Post-Surgical Care (Within 1 Year of Surgery)*, Adjusted Odds Ratio (95% CI) 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, year of diagnosis and registry. Bold indicates p<0.05.  
 
In this sensitivity analysis which evaluates receipt of post-surgical care within 1 year of surgery, we continue to find that at the time of diagnosis, 
patients who received adequate lymph node evaluation were also more likely to receive recommended post-surgical care (adjuvant chemotherapy, 
CEA testing, and colonoscopy), with the exception CT scans. However, among patients who survived to the end of the eligibility period for post-
surgical care, we found that individuals with adequate lymph node evaluation were no more likely to receive recommended post-surgical care than 
those with <12 nodes evaluated (p>0.05 for all). 
 Computed Tomography (CT) Scan of the 
Chest or Abdomen within 1 Year of 
Surgical Treatment 
Carcinoembryonic Antigen (CEA) Test within 
1 year of Surgical Treatment 
  All Patients 
(N=17,906) 
1 Year Survivors 
(N=10,016) 
 All Patients 
(N=17,906) 
1 Year Survivors 
(N=10,016) 
Lymph Nodes Evaluated     
<12 Ref Ref Ref Ref 
≥12 1.01 [0.95, 1.07] 0.94 [0.88, 1.01] 1.17 [1.10, 1.26] 1.09 [1.00, 1.18] 
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Appendix 14a: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon Cancer Patients, Alternate Timing for Receipt of 
Post-Surgical Care (Within 5 Years of Surgery)*, Adjusted Odds Ratio (95% CI) 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, year of diagnosis and registry. Bold indicates p<0.05.  
 
 
 Chemotherapy Receipt within 12 Months 
of Diagnosis 
Colonoscopy within 12 months of Surgical 
Treatment 
  All Patients 
(N=17,906) 
12 Month Survivors            
(N= 15, 581) 
 All Patients 
(N=17,906) 
12 Month Survivors            
(N= 15, 581) 
Lymph Nodes Evaluated     
<12 Ref Ref Ref Ref 
≥12 1.07 [1.00, 1.15] 0.99 [0.91, 1.07] 1.11 [1.04, 1.20] 1.06 [0.97, 1.15] 
 i  i i  5 Years of 
Diagnosis (N/A) 
Colonoscopy within 5 Years of Surgical 
1 Year Survi ors            5 Year Survi ors            
- - 
- - 3 6 1 0 94 83 0
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Appendix 14b: Predictors of Guideline Recommended Post-Surgical Care for AJCC Stage III Colon Cancer Patients, Alternate Timing for Receipt of 
Post-Surgical Care (Within 5 Years of Surgery)*, Adjusted Odds Ratio (95% CI) 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, year of diagnosis and registry. Bold indicates p<0.05.  
 
In this sensitivity analysis which evaluates receipt of post-surgical care within 5 years of surgery, we continue to find that at the time of diagnosis, 
patients who received adequate lymph node evaluation were also more likely to receive recommended post-surgical care (CEA testing and 
colonoscopy), with the exception CT scans. Receipt of adjuvant chemotherapy was not assessed as recommendations all fall within 1 year of 
diagnosis. However, among patients who survived to the end of the eligibility period for post-surgical care, we found that individuals with 
adequate lymph node evaluation were no more likely to receive recommended post-surgical care than those with <12 nodes evaluated (p>0.05 for 
all). 
 
 Computed Tomography (CT) Scan of the 
Chest or Abdomen within 5 Years of 
Surgical Treatment 
Carcinoembryonic Antigen (CEA) Test within 
5 years of Surgical Treatment 
  All Patients 
(N=17,906) 
5 Year Survivors 
(N=10,016) 
 All Patients 
(N=17,906) 
5 Year Survivors 
(N=10,016) 
Lymph Nodes Evaluated     
<12 Ref Ref Ref Ref 
≥12 1.02 [0.95, 1.09] 0.92 [0.84, 1.00] 1.21 [1.12, 1.30] 1.00 [1.00, 1.26] 
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Appendix 15: Interaction Analyses between the Level of Lymph Node Evaluation and 
Patient Factors, Logistic Regression Models Evaluating the Association between Lymph 
Node Evaluation and Receipt of Post-Surgical Care 
The following sensitivity analyses evaluate the presence of a significant interaction between the 
level of lymph node evaluation a patient receives and other characteristics of those patients. 
Specifically, we assessed whether a significant interaction was present between the level of 
lymph node evaluation and patient age, race, sex, t-stage, and tumor grade. A significant 
interaction would indicate that the association between lymph node evaluation and receipt of 
post-surgical care varied by one or multiple of these patient characteristics. We used the 
likelihood ratio test to evaluate the presence of a significant interaction in our models.84 The 
likelihood ratio test uses the ratio of the maximized value of the likelihood function for the 
interaction model (L1) over the maximized value of the likelihood function for the full model 
(L0). The likelihood test statistic equals:   
 
This log transformation of the likelihood function yields a chi-square statistic. We considered a p-
value for this chi-square statistic of <0.05 to be significant.   
 
For all interaction analyses, the Full model indicates a logistic regression model evaluating the 
association between lymph node evaluation and receipt of post-surgical care, adjusting for patient 
age, race, sex, T-stage, tumor grade, tumor location, Charlson score, year of diagnosis and 
registry. 
 
Receipt of Chemotherapy within 6 months of Diagnosis (N=17,906) 
LN Evaluation*Age Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 19576.23   
Full Model + Interaction 
term between LN 
Evaluation*age (L1) 
19571.82 4 >0.25 
Difference 4.41   
 
 
LN Evaluation*Race Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 19576.23   
Full Model + Interaction 
term between LN 
Evaluation*Race (L1) 
19575.29 2 >0.25 
Difference 0.94   
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Appendix 15 (Continued): Interaction Analyses between the Level of Lymph Node 
Evaluation and Patient Factors, Logistic Regression Model Evaluating the Association 
between Lymph Node Evaluation and Receipt of Post-Surgical Care 
 
Receipt of Chemotherapy within 6 months of Diagnosis (N=17,906) 
LN Evaluation*Sex Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 19576.23   
Full Model + Interaction 
term between LN 
Evaluation*Sex (L1) 
19576.16 1 >0.25 
Difference 0.07   
 
LN Evaluation*T-stage Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 19576.23   
Full Model + Interaction 
term between LN 
Evaluation*T-stage (L1) 
19573.75 3 >0.25 
Difference 2.48   
 
LN Evaluation*Charlson Score Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 19576.23   
Full Model + Interaction 
term between LN 
Evaluation*Tumor 
Grade (L1) 
19569.86 3 0.10 
Difference 6.37   
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Appendix 15 (Continued): Interaction Analyses between the Level of Lymph Node 
Evaluation and Patient Factors, Logistic Regression Model Evaluating the Association 
between Lymph Node Evaluation and Receipt of Post-Surgical Care 
 
Colonoscopy within 3 Years of Surgical Treatment (N=17,906) 
LN Evaluation*Age Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 22400.86   
Full Model + Interaction 
term between LN 
Evaluation*age (L1) 
22395.02 4 0.25 
Difference 5.84   
 
LN Evaluation*Race Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 22400.86   
Full Model + Interaction 
term between LN 
Evaluation*Race (L1) 
22400.15 2 >0.25 
Difference 0.71   
 
LN Evaluation*Sex Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 22400.86   
Full Model + Interaction 
term between LN 
Evaluation*Sex (L1) 
22400.85 1 >0.25 
Difference 0.01   
 
LN Evaluation*T-stage Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 22400.86   
Full Model + Interaction 
term between LN 
Evaluation*T-stage (L1) 
22397.38 3 >0.25 
Difference 3.48   
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Appendix 15 (Continued): Interaction Analyses between the Level of Lymph Node 
Evaluation and Patient Factors, Logistic Regression Model Evaluating the Association 
between Lymph Node Evaluation and Receipt of Post-Surgical Care 
 
Colonoscopy within 3 Years of Surgical Treatment (N=17,906) 
 
LN Evaluation*Charlson Score Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 22400.86   
Full Model + Interaction 
term between LN 
Evaluation*Tumor 
Grade (L1) 
22396.69 3 0.25 
Difference 4.17   
 
CT Scan within 3 Years of Surgical Treatment (N=17,906) 
 
LN Evaluation*Age Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 20949.44   
Full Model + Interaction 
term between LN 
Evaluation*age (L1) 
20947.39 4 >0.25 
Difference 2.05   
 
LN Evaluation*Race Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 20949.44   
Full Model + Interaction 
term between LN 
Evaluation*Race (L1) 
20946.22 2 0.20 
Difference 3.22   
 
LN Evaluation*Sex Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 20949.44   
Full Model + Interaction 
term between LN 
Evaluation*Sex (L1) 
20949.00 1 >0.25 
Difference 0.44   
 
 
 
 
 123 
Appendix 15 (Continued): Interaction Analyses between the Level of Lymph Node 
Evaluation and Patient Factors, Logistic Regression Model Evaluating the Association 
between Lymph Node Evaluation and Receipt of Post-Surgical Care 
 
 
CT Scan within 3 Years of Surgical Treatment (N=17,906) 
LN Evaluation*T-stage Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 20949.44   
Full Model + Interaction 
term between LN 
Evaluation*T-stage (L1) 
20944.60 3 0.20 
Difference 4.8   
 
 
LN Evaluation*Charlson Score Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 20949.44   
Full Model + Interaction 
term between LN 
Evaluation*Tumor 
Grade (L1) 
20944.58 3 0.20 
Difference 4.78   
 
CEA Test within 3 Years of Surgical Treatment (N=17,906) 
LN Evaluation*Age Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 18746.69   
Full Model + Interaction 
term between LN 
Evaluation*age (L1) 
18743.87 4 >0.25 
Difference 2.82   
 
LN Evaluation*Race Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 18746.69   
Full Model + Interaction 
term between LN 
Evaluation*Race (L1) 
18744.59 2 >0.25 
Difference 2.1   
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Appendix 15 (Continued): Interaction Analyses between the Level of Lymph Node 
Evaluation and Patient Factors, Logistic Regression Model Evaluating the Association 
between Lymph Node Evaluation and Receipt of Post-Surgical Care 
 
 
CEA Test within 3 Years of Surgical Treatment (N=17,906) 
 
LN Evaluation*Sex Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 18746.69   
Full Model + Interaction 
term between LN 
Evaluation*Sex (L1) 
18745.88 1 >0.25 
Difference 0.81   
 
 
LN Evaluation*T-stage Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 18746.69   
Full Model + Interaction 
term between LN 
Evaluation*T-stage (L1) 
18740.52 3 0.10 
Difference 6.17   
 
 
LN Evaluation*Charlson Score Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 18746.69   
Full Model + Interaction 
term between LN 
Evaluation*Tumor 
Grade (L1) 
18742.81 3 >0.25 
Difference 3.88   
 
The interaction terms for LN Evaluation and age, race, sex and T-stage and Charlson score were 
all non-significant for models assessing the association between the level of lymph node 
evaluation and receipt of chemotherapy, colonoscopy, CT scans and CEA testing. These 
sensitivity analyses indicate that the relationship between lymph node evaluation and receipt of 
post-surgical care is consistent across the patient factors evaluated. Therefore, our conclusions 
about the relationship between lymph node evaluation and receipt of post-surgical care remain 
unchanged.   
 
 
 125 
Appendix 16: Interaction Analyses between the Level of Lymph Node Evaluation and 
Patient Factors, Cox Proportional Hazards Model Evaluating the Association between 
Lymph Node Evaluation and 10-Year Relative Hazard of Death (N=17,906) 
The following sensitivity analyses evaluate the presence of a significant interaction between the 
level of lymph node evaluation a patient receives and other characteristics of those patients. 
Specifically, we assessed whether a significant interaction was present between the level of 
lymph node evaluation and patient age, race, sex, t-stage, and tumor grade. A significant 
interaction would indicate that the association between lymph node evaluation and 10-year 
relative hazard of death varied by one or multiple of these patient characteristics. We used the 
likelihood ratio test to evaluate the presence of a significant interaction in our models.84 The 
likelihood ratio test uses the ratio of the maximized value of the likelihood function for the 
interaction model (L1) over the maximized value of the likelihood function for the full model 
(L0). The likelihood test statistic equals:   
 
This log transformation of the likelihood function yields a chi-square statistic. We considered a p-
value for this chi-square statistic of <0.05 to be significant.   
 
For all interaction analyses, the Full model indicates a logistic regression model evaluating the 
association between lymph node evaluation and 10-year relative hazard of death, adjusting for 
patient age, race, sex, T-stage, tumor grade, tumor location, Charlson score, year of diagnosis, 
registry, receipt of chemotherapy, receipt of colonoscopy, receipt of CT scans, and receipt of 
CEA testing. 
 
LN Evaluation*Age Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 213557.92   
Full Model + Interaction 
term between LN 
Evaluation*age (L1) 
213552.25 4 0.25 
Difference 5.67   
 
LN Evaluation*Race Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 213557.92   
Full Model + Interaction 
term between LN 
Evaluation*Race (L1) 
213557.60 2 >0.25 
Difference 0.32   
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Appendix 16 (continued): Interaction Analyses between the Level of Lymph Node 
Evaluation and Patient Factors, Cox Proportional Hazards Model Evaluating the 
Association between Lymph Node Evaluation and 10-Year Relative Hazard of Death 
 
LN Evaluation*Sex Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 213557.92   
Full Model + Interaction 
term between LN 
Evaluation*Sex (L1) 
213557.51 1 >0.25 
Difference 0.41   
 
LN Evaluation*T-stage Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 213557.92   
Full Model + Interaction 
term between LN 
Evaluation*T-stage (L1) 
213557.24 3 >0.25 
Difference 0.64   
 
LN Evaluation*Charlson Score Interaction 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 213557.92   
Full Model + Interaction 
term between LN 
Evaluation*Tumor 
Grade (L1) 
213553.47 3 0.25 
Difference 4.45   
 
The interaction terms for LN Evaluation and age, race, sex and T-stage and Charlson score were 
all non-significant for models assessing the association between the level of lymph node 
evaluation and 10-year relative hazard of death. These sensitivity analyses indicate that the 
relationship between lymph node evaluation and 10-year hazard of death is consistent across the 
patient factors evaluated. Therefore, our conclusions about the relationship between lymph node 
evaluation and 10-year relative hazard of death remain unchanged.   
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Appendix 17: Unadjusted Association between the Number of Lymph Nodes Evaluated and the Number of Positive Lymph Nodes 
Identified Among AJCC Stage III Colon Cancer Patients, %* (N) (N=17,906) 
 
 Number of Lymph Nodes Evaluated 
Tumor N Category <12 LNs Evaluated ≥12 LNs Evaluated 
N1 (1-3 Positive Nodes) 74.9 (6,268) 62.2 (5,931)  
N2 (≥4 Positive Nodes) 23.7 (1,987) 37.0 (3,531) 
Nx (Incomplete Information) 1.4 (119) 0.7 (70) 
*p<0.001; N1: Cancer cells found in 1-3 nearby lymph nodes; N2: Cancer cells found in ≥4 nearby lymph nodes; Nx: Incomplete information on 
the number of positive nodes53 
 
In this sensitivity analysis, we find that the number of positive lymph nodes identified is associated with the number of lymph nodes evaluated. 
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Appendix 18: Association between the Number of Positive Lymph Nodes Identified and Receipt of Post-Surgical Care Among AJCC 
Stage III Colon Cancer Patients, * Adjusted Odds Ratio (95% CI) with the Number of Positive Nodes Included     
% (N) (N=17,906) 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, Charlson score, year of diagnosis and registry. Bold indicates p<0.05.  
N1: Cancer cells found in 1-3 nearby lymph nodes; N2: Cancer cells found in ≥4 nearby lymph nodes; Nx: Incomplete information on the number 
of positive nodes53 
 
 Chemotherapy Receipt within 6 Months 
of Diagnosis 
Colonoscopy within 3 Years of Surgical 
Treatment 
  All Patients 
(N=17,906) 
6 Month Survivors            
(N= 15, 581) 
 All Patients 
(N=17,906) 
6 Month Survivors            
(N= 15, 581) 
Number of Positive Lymph Nodes     
N1 (1-3 Positive Nodes) Ref Ref Ref Ref 
N2 (≥4 Positive Nodes) 1.25 [1.16, 1.35] 1.44 [1.32, 1.57] 0.70 [0.66, 0.75] 0.99 [0.89, 1.10] 
Nx (Incomplete Information) 0.21 [0.14, 0.30] 0.18 [0.12, 0.28] 0.89 [0.66, 1.22] 0.73 [0.51, 1.06] 
Lymph Nodes Evaluated     
<12 Ref  Ref Ref Ref 
≥12 1.05 [0.98, 1.13] 0.96 [0.88, 1.04] 1.17 [1.09, 1.25] 0.98, [0.73, 1.31] 
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Appendix 18(Continued): Association between the Number of Positive Lymph Nodes Identified and Receipt of Post-Surgical Care Among 
AJCC Stage III Colon Cancer Patients, * Adjusted Odds Ratio (95% CI) with the Number of Positive Nodes Included     
% (N) (N=17,906) 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, Charlson score, year of diagnosis and registry. Bold indicates p<0.05.  
N1: Cancer cells found in 1-3 nearby lymph nodes; N2: Cancer cells found in ≥4 nearby lymph nodes; Nx: Incomplete information on the number 
of positive nodes53 
 
In this sensitivity analysis, we found that the number of positive nodes identified is associated with receiving chemotherapy, CT scans and CEA 
testing, but not colonoscopy. However, when we adjust for the number of positive nodes identified from a patient, our conclusions about the 
association between more extensive lymph node evaluation and receipt of post-surgical care do not change.  
 Computed Tomography (CT) Scan of the 
Chest or Abdomen within 3 Years of 
Surgical Treatment 
Carcinoembryonic Antigen (CEA) Test within 
3 years of Surgical Treatment 
  All Patients 
(N=17,906) 
3 Year Survivors 
(N=10,016) 
 All Patients 
(N=17,906) 
3 Year Survivors 
(N=10,016) 
Number of Positive Lymph Nodes     
N1 (1-3 Positive Nodes) Ref Ref Ref Ref 
N2 (≥4 Positive Nodes) 1.26 [1.17, 1.36] 1.37 [1.23, 1.54] 0.95 [0.88, 1.03] 1.31 [1.12, 1.53] 
Nx (Incomplete Information) 0.51 [0.38, 0.70] 0.43 [0.30, 0.61] 0.56 [0.41, 0.78] 0.36 [0.24, 0.54] 
Lymph Nodes Evaluated     
<12 Ref  Ref Ref Ref 
≥12 1.02 [0.95, 1.09] 0.92 [0.83, 1.01] 1.21 [1.13, 1.31] 1.08, [0.95, 2.06] 
 130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, Charlson score, year of diagnosis and registry. Bold indicates p<0.05.  
N1: Cancer cells found in 1-3 nearby lymph nodes; N2: Cancer cells found in ≥4 nearby lymph nodes; Nx: Incomplete information on the number 
of positive nodes53 
 
In this sensitivity analysis, we found that the number of positive nodes identified is associated with 10-year relative hazard of death among all 
patients and 3-year survivors. However, when we adjust for the number of positive nodes identified from a patient, our conclusions about the 
association between more extensive lymph node evaluation and 10-year relative hazard of death remain unchanged.  
Appendix 19: Factors Associated with 10-Year Relative Hazard of Death Among AJCC Stage III Colon Cancer Patients, Cox 
Proportional Hazard Models, Hazard Ratio Adjusting for Number of Positive Nodes, 95% CI 
 All Patients (N=17,906) 3-Year Survivors (N=10, 016) 
  Model 1 Model 2 Model 3  Model 4 
Lymph Nodes Evaluated         
<12  Ref Ref Ref Ref 
≥12  0.82 (0.79, 0.85) 0.83 (0.80, 0.86) 0.91 (0.86, 0.97) 0.91 (0.85, 0.97) 
Number of Positive Lymph 
Nodes     
N1 Ref Ref Ref Ref 
N2 1.53 (1.47, 1.59) 1.56 (1.50, 1.62) 1.29 (1.20, 1.39) 1.31 (1.21, 1.41) 
Nx 0.70(0.57, 0.86) 0.61 (0.50, 0.75) 0.83(0.62, 1.12) 0.77 (0.57, 1.04) 
Guideline Recommended Post-Surgical Care     
Chemotherapy within 6 months of 
diagnosis   0.78 (0.74, 0.82)   0.71 (0.65, 0.77) 
Colonoscopy within 3 years of 
surgery   0.42 (0.40, 0.44)   0.68 (0.64, 0.74) 
CT scan within 3 years of surgery   1.27 (1.22, 1.32)   1.57 (1.45, 1.69) 
CEA within 3 years of surgery   0.49 (0.47, 0.51)   0.83 (0.76, 0.92) 
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Appendix 20: Factors Associated with 10-Year Relative Hazard of Death Among AJCC Stage III Colon Cancer Patients, Cox Proportional Hazard 
Models, Hazard Ratio Adjusting for Each Type of Post-Surgical Care Separately, 95% CI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, Charlson score, year of diagnosis and registry. Bold indicates p<0.05. 
In this sensitivity analysis, we find that the association between the level of lymph node evaluation and 10-year relative hazard of death remains 
consistent when the model is adjusted for each type of post-surgical care separately. However, we do find that the relationship between receipt of 
CT scans and 10-year relative hazard of death changes direction when all types of post-surgical care are included in the model (see Table 11).   
We, therefore conducted additional sensitivity analyses to evaluate potential interactions between receipt of CT scans and other patient factors (see 
appendix 21).  
 All Patients (N=17,906) 
  Model 1 Model 2 Model 3  Model 4 
Lymph Nodes Evaluated         
<12  Ref Ref Ref Ref 
≥12  0.85 (0.82, 0.89) 0.86 (0.83, 0.89) 0.86 (0.82, 0.88) 0.88 (0.85, 0.91) 
Guideline Recommended Post-Surgical Care     
Chemotherapy within 6 
months of diagnosis  0.50 (0.48, 0.52)    
Colonoscopy within 3 years 
of surgery   0.34 (0.33, 0.35)   
CT scan within 3 years of 
surgery    0.86 (0.83, 0.89)  
CEA within 3 years of 
surgery     0.37 (0.35, 0.38) 
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Appendix 21: Interaction analyses between Receipt of CT Scans and Charlson Score on 10-Year Relative Hazard of Death Among AJCC Stage III 
Colon Cancer Patients, Cox Proportional Hazards Model 95% CI 
 
 
 
The following sensitivity analysis evaluate the presence of a significant interaction between receipt of CT scans and patient factors when assessing 
the association between receipt of CT scans and 10-year relative hazard of death. See Appendix 16 for a more complete description of how the 
interaction analyses were performed. Specifically, we evaluated whether an interaction was present between receipt of CT scans and a patient’s 
age, race, sex, T-stage and Charlson score. We only found a significant interaction between receipt of CT scans and a patient’s charlson 
comorbidity score (below) and, therefore, evaluated the association between lymph node evaluation and receipt of post-surgical care on 10-year 
relative hazard of death stratified by patients’ comorbidity scores (See Appendix 22).  
 
 
 
 
Receipt of CT Scans within 3-Years of Surgery*Charlson Score Interaction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 -2 Log Likelihood Degrees of 
Freedom 
P-value 
Full Model (L0) 213557.92   
Full Model + Interaction 
term between LN 
Evaluation*Tumor 
Grade (L1) 
213480.19 3 <0.001 
Difference 77.7   
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Appendix 22: Association between Lymph Node Evaluation and Receipt of Post-Surgical Care on 10-Year Relative Hazard of Death Among AJCC 
Stage III Colon Cancer Patients, Cox Proportional Hazards Model 95% CI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Also adjusted for age, sex, race, T-stage, tumor grade, tumor location, year of diagnosis and registry. Bold indicates p<0.05. 
In this sensitivity analysis, we find that the association between the level of lymph node evaluation and 10-year relative hazard of death remains 
consistent when the model is adjusted for each type of post-surgical care separately. However, we do find that the relationship between receipt of 
CT scans and 10-year relative hazard of death changes direction when we stratify our models by patients’ Charlson score (see Table 11). 
Specifically, we find that among healthier patients (Charlson score=0), receipt of each type of post-surgical care is associated (See following page)  
Appendix 22 (Continued) 
 
 
 
  Charlson Score=0 Charlson Score=1 Charlson Score=2  Charlson Score=3 
Number of Patients 11,178 3,193 1,694 1,841 
Lymph Nodes Evaluated         
<12  Ref Ref Ref Ref 
≥12  0.86 (0.82, 0.91) 0.88 (0.81, 0.97) 1.00 (0.90, 1.15) 0.92 (0.83, 1.03) 
Guideline Recommended Post-Surgical Care     
Chemotherapy within 6 
months of diagnosis 0.80 (0.79, 0.92) 0.80 (0.69, 0.93) 0.76 (0.68, 0.85) 0.82 (0.77, 0.87) 
Colonoscopy within 3 years 
of surgery 0.46 (0.40, 0.52) 0.41 (0.36, 0.47) 0.45 (0.41, 0.50) 0.38 (0.36, 0.40) 
CT scan within 3 years of 
surgery 0.83 (0.73, 0.93) 1.07 (0.94, 1.22) 1.22 (1.10, 1.34) 1.53 (1.45, 1.63) 
CEA within 3 years of 
surgery 0.49 (0.43, 0.56) 0.52 (0.44, 0.60) 0.45 (0.41, 0.50) 0.49 (0.46, 0.53) 
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(Continued from previous page) … with lower 10-year relative hazard of death. However, as the number of comorbidities patients’ have increases, 
receipt of CT scans becomes associated with higher 10-year relative hazard of death. Because we do not know the reason for the CT scan 
(surveillance or symptom-driven), it’s possible these patients have other competing illness or reduced immune system response that may be 
associated with higher likelihood of death that is not measured in our model. However, under all assumptions, the relative association between 
lymph node evaluation and 10-year hazard of death remains unchanged. 
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Appendix 23: Chapter 5 Patient and Hospital Inclusion Criteria 
Inclusion Criteria 
Number of Patients 
Excluded 
Subtotal Remaining 
(Patients) 
Subtotal Remaining 
(Hospitals) 
Clinical and Treatment Inclusion Criteria (SEER)   
Diagnosed with a first 
primary AJCC Stage I-
IIII adenocarcinoma of 
the colon between 
1992-2007 (Appendix 
B) in Registries 
reporting cases from 
1992-2007   54,003 N/A 
Over age 66 at 
diagnosis according to 
SEER and Medicare 1,944 52,059 N/A 
Not diagnosed by 
autopsy or death 
certificate 47 52,012 N/A 
Known Month of 
Diagnosis 46 51,966 N/A 
No pre-operative 
radiation 49 51,917 N/A 
Radical Exision 
Performed, according 
to SEER (Appendix B) 3,052 48,865 N/A 
Known number of 
lymph nodes surgically 
evaluated 935 47,930 N/A 
Medicare Enrollment Inclusion Criteria   
Enrolled in Medicare 
Part A + B six months 
prior to six months 
post diagnosis 2,817 45,113 N/A 
No HMO enrollment 
six months prior to six 
months post diagnosis 12,271 32,842 N/A 
(Continued on the following page) 
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Treatment Inclusion Criteria (Medicare Claims-based Evidence)   
Hospitalization record 
for radical excision of 
the colon within six 
months of diagnosis 2,981 29,861 695 
Only one 
Hospitalization record 
for radical excision 
within six months of 
diagnosis 821 29,040 686 
Hospital Inclusion 
Criteria       
Treated in a hospital 
present in the 
Medicare data from 
1992-2007 1,182 27,858 381 
Hospitals had at least 
6 surgeries during 
each study period (i.e. 
performing 
approximately 2 per 
year) 2,932 24,926 228 
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Appendix 24: Hospital Factors associated with  Improvement or Maintenance of Adequate Lymph Node Evaluation (i.e. Median LN Evaluation ≥11),  
Odds Ratios (95% CI)* 
    
  
Short-Term  
(1999-2001 vs. 1996-1998)  
Medium-Term  
(2002-2004 vs. 1996-1998) 
Long-Term  
(2005-2007 vs. 1996-1998) 
Initial Median LN Evaluation ≥11 (1996-1998) Ref. Ref. Ref. 
Yes  6.26       (2.95, 13.28)* 2.66      (1.32, 5.37)* 2.13       (0.91, 4.98) 
Teaching Hospital       
No Ref. Ref. Ref. 
Yes 0.91       (0.39, 2.13) 1.08       (0.50, 2.34) 0.89       (0.37, 2.11) 
Hospital Ownership       
Non-Profit Ref. Ref. Ref. 
For-Profit 0.73      (0.24, 2.24) 0.37       (0.13, 1.09) 0.61       (0.21, 1.84) 
Government 1.19       (0.46, 3.11) 1.58      (0.65, 3.84) 1.64       (0.59, 4.55) 
Hospital Volume 1996-1998  (Quartiles)       
1 (6-13  procedures) Ref. Ref. Ref. 
2 ( 14-21 procedures) 0.79       (0.30, 2.08) 2.28       (0.93, 5.61)  1.60       (0.62, 4.13) 
3 (22-37 procedures) 0.75       (0.27, 2.04) 2.77       (1.06, 7.21) 1.28       (0.46, 3.55) 
4 (≥38 procedures) 0.95       (0.29, 3.04) 0.67       (0.22, 2.10) 2.17       (0.55, 8.70) 
Hospital Location       
Rural Ref. Ref. Ref. 
Urban 2.95       (0.99, 7.92) 2.41       (1.03, 5.60) 2.75       (1.12, 6.77) 
ACOSOG Member              (Assessed in 2002)                                          
No Ref. Ref. Ref. 
Yes 1.37       (0.52, 3.62) 1.92       (0.69, 5.35)  2.05      (0.50, 8.52) 
C-Statistic 0.83 0.78 0.78 
*Also Adjusted for Hospital-Level patient factors including: % of patients ≥80 years of age, % non-white patients, % of male patients, % of proximal 
tumors, % of high grade tumors, % of patients with a high Charlson score (≥3), % high staged (AJCC Stage III) cancers treated by the hospital.  
Number of Patients 10,605 12,899 11,820 
Number of Hospitals 228 228 228 
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Appendix 25: Hospital Factors associated with  Improvement or Maintenance of Adequate Lymph Node Evaluation (i.e. Median LN Evaluation ≥13),  
Odds Ratios (95% CI)* 
    
  
Short-Term  
(1999-2001 vs. 1996-1998)  
Medium-Term  
(2002-2004 vs. 1996-1998) 
Long-Term  
(2005-2007 vs. 1996-1998) 
Initial Median LN Evaluation ≥13 (1996-1998) Ref. Ref. Ref. 
Yes  3.99       (1.68, 9.53)* 3.16       (1.42, 7.04)* 1.85       (0.79, 4.35) 
Teaching Hospital       
No Ref. Ref. Ref. 
Yes 1.71       (0.60, 4.94) 1.26       (0.54, 2.93) 0.91       (0.44, 1.90) 
Hospital Ownership       
Non-Profit Ref. Ref. Ref. 
For-Profit 0.54      (0.11, 2.73) 0.62       (0.20, 1.91) 1.63       (0.60, 4.45) 
Government 0.70       (0.20, 2.41) 1.16       (0.45, 2.94) 1.12       (0.49, 2.55) 
Hospital Volume 1996-1998  (Quartiles)       
1 (6-13  procedures) Ref. Ref. Ref. 
2 ( 14-21 procedures) 0.77       (0.21, 2.75) 2.69       (0.98, 7.37)  1.47       (0.64, 3.38) 
3 (22-37 procedures) 0.94       (0.27, 3.31) 2.41       (0.84, 6.96) 1.33       (0.55, 3.17) 
4 (≥38 procedures) 1.29       (0.32, 5.16) 1.18       (0.36, 3.91) 1.36       (0.45, 4.09) 
Hospital Location       
Rural Ref. Ref. Ref. 
Urban 1.26       (0.40, 4.04) 2.31       (0.91, 5.87) 1.43       (0.65, 3.13) 
ACOSOG Member             (Assessed in 2002)                                                      
No Ref. Ref. Ref. 
Yes 3.10       (1.12, 8.55)* 3.05       (1.22, 7.59)*  2.46      (0.85, 7.16) 
C-Statistic 0.81 0.79 0.74 
*Also Adjusted for Hospital-Level patient factors including: % of patients ≥80 years of age, % non-white patients, % of male patients, % of proximal 
tumors, % of high grade tumors, % of patients with a high Charlson score (≥3), % high staged (AJCC Stage III) cancers treated by the hospital.  
Number of Patients 10,605 12,899 11,820 
Number of Hospitals 228 228 228 
 
